id	sid	tid	token	lemma	pos
dpc-1907	1	1	dermatology	dermatology	NOUN
dpc-1907	1	2	:	:	PUNCT
dpc-1907	1	3	practical	practical	ADJ
dpc-1907	1	4	and	and	CCONJ
dpc-1907	1	5	conceptual	conceptual	ADJ
dpc-1907	1	6	original	original	ADJ
dpc-1907	1	7	article	article	NOUN
dpc-1907	1	8	|	|	ADV
dpc-1907	1	9	dermatol	dermatol	ADJ
dpc-1907	1	10	pract	pract	NOUN
dpc-1907	1	11	concept	concept	NOUN
dpc-1907	1	12	.	.	PUNCT
dpc-1907	2	1	2022;12(2):e2022076	2022;12(2):e2022076	NUM
dpc-1907	2	2	1	1	NUM
dpc-1907	2	3	dermatology	dermatology	NOUN
dpc-1907	2	4	practical	practical	ADJ
dpc-1907	2	5	&	&	CCONJ
dpc-1907	2	6	conceptual	conceptual	ADJ
dpc-1907	2	7	apremilast	apremilast	PROPN
dpc-1907	2	8	survival	survival	NOUN
dpc-1907	2	9	and	and	CCONJ
dpc-1907	2	10	reasons	reason	NOUN
dpc-1907	2	11	for	for	ADP
dpc-1907	2	12	discontinuation	discontinuation	NOUN
dpc-1907	2	13	in	in	ADP
dpc-1907	2	14	psoriasis	psoriasis	NOUN
dpc-1907	2	15	:	:	PUNCT
dpc-1907	2	16	five	five	NUM
dpc-1907	2	17	-	-	PUNCT
dpc-1907	2	18	year	year	NOUN
dpc-1907	2	19	experience	experience	NOUN
dpc-1907	2	20	from	from	ADP
dpc-1907	2	21	a	a	DET
dpc-1907	2	22	greek	greek	ADJ
dpc-1907	2	23	tertiary	tertiary	ADJ
dpc-1907	2	24	care	care	NOUN
dpc-1907	2	25	centre	centre	PROPN
dpc-1907	2	26	elena	elena	PROPN
dpc-1907	2	27	sotiriou1	sotiriou1	PROPN
dpc-1907	2	28	,	,	PUNCT
dpc-1907	2	29	aikaterini	aikaterini	PROPN
dpc-1907	2	30	tsentemeidou1	tsentemeidou1	PROPN
dpc-1907	2	31	,	,	PUNCT
dpc-1907	2	32	nikolaos	nikolaos	PROPN
dpc-1907	2	33	sideris1	sideris1	PROPN
dpc-1907	2	34	,	,	PUNCT
dpc-1907	2	35	aimilios	aimilios	PROPN
dpc-1907	2	36	lallas1	lallas1	PROPN
dpc-1907	2	37	,	,	PUNCT
dpc-1907	2	38	nikolaos	nikolaos	PROPN
dpc-1907	2	39	kougkas2	kougkas2	PROPN
dpc-1907	2	40	,	,	PUNCT
dpc-1907	2	41	dimitrios	dimitrios	PROPN
dpc-1907	2	42	ioannides1	ioannides1	PROPN
dpc-1907	2	43	,	,	PUNCT
dpc-1907	2	44	efstratios	efstratio	NOUN
dpc-1907	2	45	vakirlis1	vakirlis1	VERB
dpc-1907	2	46	1	1	NUM
dpc-1907	2	47	first	first	ADJ
dpc-1907	2	48	department	department	NOUN
dpc-1907	2	49	of	of	ADP
dpc-1907	2	50	dermatology	dermatology	NOUN
dpc-1907	2	51	and	and	CCONJ
dpc-1907	2	52	venereology	venereology	NOUN
dpc-1907	2	53	,	,	PUNCT
dpc-1907	2	54	school	school	NOUN
dpc-1907	2	55	of	of	ADP
dpc-1907	2	56	medicine	medicine	NOUN
dpc-1907	2	57	,	,	PUNCT
dpc-1907	2	58	aristotle	aristotle	PROPN
dpc-1907	2	59	university	university	PROPN
dpc-1907	2	60	,	,	PUNCT
dpc-1907	2	61	thessaloniki	thessaloniki	PROPN
dpc-1907	2	62	,	,	PUNCT
dpc-1907	2	63	greece	greece	PROPN
dpc-1907	2	64	2	2	NUM
dpc-1907	2	65	fourth	fourth	PROPN
dpc-1907	2	66	department	department	NOUN
dpc-1907	2	67	of	of	ADP
dpc-1907	2	68	internal	internal	ADJ
dpc-1907	2	69	medicine	medicine	NOUN
dpc-1907	2	70	,	,	PUNCT
dpc-1907	2	71	aristotle	aristotle	PROPN
dpc-1907	2	72	university	university	PROPN
dpc-1907	2	73	of	of	ADP
dpc-1907	2	74	thessaloniki	thessaloniki	PROPN
dpc-1907	2	75	,	,	PUNCT
dpc-1907	2	76	greece	greece	PROPN
dpc-1907	2	77	.	.	PUNCT
dpc-1907	3	1	key	key	ADJ
dpc-1907	3	2	words	word	NOUN
dpc-1907	3	3	:	:	PUNCT
dpc-1907	3	4	psoriasis	psoriasis	NOUN
dpc-1907	3	5	,	,	PUNCT
dpc-1907	3	6	apremilast	apremilast	ADJ
dpc-1907	3	7	,	,	PUNCT
dpc-1907	3	8	survival	survival	NOUN
dpc-1907	3	9	,	,	PUNCT
dpc-1907	3	10	discontinuation	discontinuation	NOUN
dpc-1907	3	11	,	,	PUNCT
dpc-1907	3	12	greece	greece	PROPN
dpc-1907	3	13	citation	citation	PROPN
dpc-1907	3	14	:	:	PUNCT
dpc-1907	3	15	sotiriou	sotiriou	NOUN
dpc-1907	3	16	e	e	NOUN
dpc-1907	3	17	,	,	PUNCT
dpc-1907	3	18	tsentemeidou	tsentemeidou	NOUN
dpc-1907	3	19	a	a	PRON
dpc-1907	3	20	,	,	PUNCT
dpc-1907	3	21	sideris	sideris	NOUN
dpc-1907	3	22	n	n	CCONJ
dpc-1907	3	23	,	,	PUNCT
dpc-1907	3	24	et	et	PROPN
dpc-1907	3	25	al	al	PROPN
dpc-1907	3	26	.	.	PROPN
dpc-1907	3	27	apremilast	apremilast	PROPN
dpc-1907	3	28	survival	survival	NOUN
dpc-1907	3	29	and	and	CCONJ
dpc-1907	3	30	reasons	reason	NOUN
dpc-1907	3	31	for	for	ADP
dpc-1907	3	32	discontinuation	discontinuation	NOUN
dpc-1907	3	33	in	in	ADP
dpc-1907	3	34	psoriasis	psoriasis	NOUN
dpc-1907	3	35	:	:	PUNCT
dpc-1907	3	36	five	five	NUM
dpc-1907	3	37	-	-	PUNCT
dpc-1907	3	38	year	year	NOUN
dpc-1907	3	39	experience	experience	NOUN
dpc-1907	3	40	from	from	ADP
dpc-1907	3	41	a	a	DET
dpc-1907	3	42	greek	greek	ADJ
dpc-1907	3	43	tertiary	tertiary	ADJ
dpc-1907	3	44	care	care	NOUN
dpc-1907	3	45	centre	centre	NOUN
dpc-1907	3	46	.	.	PUNCT
dpc-1907	4	1	dermatol	dermatol	NOUN
dpc-1907	4	2	pract	pract	PROPN
dpc-1907	4	3	concept	concept	NOUN
dpc-1907	4	4	.	.	PUNCT
dpc-1907	5	1	2022;12(2):e2022076	2022;12(2):e2022076	X
dpc-1907	5	2	.	.	PUNCT
dpc-1907	5	3	doi	doi	PROPN
dpc-1907	5	4	:	:	PUNCT
dpc-1907	5	5	https://doi.org/10.5826/dpc.1202a76	https://doi.org/10.5826/dpc.1202a76	AUX
dpc-1907	5	6	accepted	accept	VERB
dpc-1907	5	7	:	:	PUNCT
dpc-1907	5	8	december	december	PROPN
dpc-1907	5	9	7	7	NUM
dpc-1907	5	10	,	,	PUNCT
dpc-1907	5	11	2021	2021	NUM
dpc-1907	5	12	;	;	PUNCT
dpc-1907	5	13	published	publish	VERB
dpc-1907	5	14	:	:	PUNCT
dpc-1907	5	15	january	january	PROPN
dpc-1907	5	16	2022	2022	NUM
dpc-1907	6	1	copyright	copyright	NOUN
dpc-1907	6	2	:	:	PUNCT
dpc-1907	6	3	©	©	PROPN
dpc-1907	6	4	2022	2022	NUM
dpc-1907	6	5	sotiriou	sotiriou	NOUN
dpc-1907	6	6	et	et	PROPN
dpc-1907	6	7	al	al	PROPN
dpc-1907	6	8	.	.	PUNCT
dpc-1907	7	1	this	this	PRON
dpc-1907	7	2	is	be	AUX
dpc-1907	7	3	an	an	DET
dpc-1907	7	4	open	open	ADJ
dpc-1907	7	5	-	-	PUNCT
dpc-1907	7	6	access	access	NOUN
dpc-1907	7	7	article	article	NOUN
dpc-1907	7	8	distributed	distribute	VERB
dpc-1907	7	9	under	under	ADP
dpc-1907	7	10	the	the	DET
dpc-1907	7	11	terms	term	NOUN
dpc-1907	7	12	of	of	ADP
dpc-1907	7	13	the	the	DET
dpc-1907	7	14	creative	creative	ADJ
dpc-1907	7	15	commons	common	NOUN
dpc-1907	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-1907	7	17	license	license	NOUN
dpc-1907	7	18	(	(	PUNCT
dpc-1907	7	19	by	by	ADP
dpc-1907	7	20	-	-	PUNCT
dpc-1907	7	21	nc-4.0	nc-4.0	NOUN
dpc-1907	7	22	)	)	PUNCT
dpc-1907	7	23	,	,	PUNCT
dpc-1907	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-1907	7	25	,	,	PUNCT
dpc-1907	7	26	which	which	PRON
dpc-1907	7	27	permits	permit	VERB
dpc-1907	7	28	unrestricted	unrestricted	ADJ
dpc-1907	7	29	noncommercial	noncommercial	ADJ
dpc-1907	7	30	use	use	NOUN
dpc-1907	7	31	,	,	PUNCT
dpc-1907	7	32	distribution	distribution	NOUN
dpc-1907	7	33	,	,	PUNCT
dpc-1907	7	34	and	and	CCONJ
dpc-1907	7	35	reproduction	reproduction	NOUN
dpc-1907	7	36	in	in	ADP
dpc-1907	7	37	any	any	DET
dpc-1907	7	38	medium	medium	NOUN
dpc-1907	7	39	,	,	PUNCT
dpc-1907	7	40	provided	provide	VERB
dpc-1907	7	41	the	the	DET
dpc-1907	7	42	original	original	ADJ
dpc-1907	7	43	authors	author	NOUN
dpc-1907	7	44	and	and	CCONJ
dpc-1907	7	45	source	source	NOUN
dpc-1907	7	46	are	be	AUX
dpc-1907	7	47	credited	credit	VERB
dpc-1907	7	48	.	.	PUNCT
dpc-1907	8	1	funding	funding	NOUN
dpc-1907	8	2	:	:	PUNCT
dpc-1907	8	3	none	none	NOUN
dpc-1907	8	4	.	.	PUNCT
dpc-1907	9	1	competing	compete	VERB
dpc-1907	9	2	interests	interest	NOUN
dpc-1907	9	3	:	:	PUNCT
dpc-1907	9	4	none	none	NOUN
dpc-1907	9	5	.	.	PUNCT
dpc-1907	10	1	irb	irb	VERB
dpc-1907	10	2	approval	approval	NOUN
dpc-1907	10	3	:	:	PUNCT
dpc-1907	11	1	ethics	ethic	NOUN
dpc-1907	11	2	committee	committee	NOUN
dpc-1907	11	3	of	of	ADP
dpc-1907	11	4	the	the	DET
dpc-1907	11	5	hospital	hospital	NOUN
dpc-1907	11	6	of	of	ADP
dpc-1907	11	7	venereal	venereal	ADJ
dpc-1907	11	8	and	and	CCONJ
dpc-1907	11	9	dermatologic	dermatologic	ADJ
dpc-1907	11	10	diseases	disease	NOUN
dpc-1907	11	11	of	of	ADP
dpc-1907	11	12	thessaloniki	thessaloniki	PROPN
dpc-1907	11	13	,	,	PUNCT
dpc-1907	11	14	greece	greece	PROPN
dpc-1907	11	15	.	.	PUNCT
dpc-1907	11	16	authorship	authorship	PROPN
dpc-1907	11	17	:	:	PUNCT
dpc-1907	11	18	all	all	DET
dpc-1907	11	19	authors	author	NOUN
dpc-1907	11	20	have	have	AUX
dpc-1907	11	21	contributed	contribute	VERB
dpc-1907	11	22	significantly	significantly	ADV
dpc-1907	11	23	to	to	ADP
dpc-1907	11	24	this	this	DET
dpc-1907	11	25	publication	publication	NOUN
dpc-1907	11	26	corresponding	correspond	VERB
dpc-1907	11	27	author	author	NOUN
dpc-1907	11	28	:	:	PUNCT
dpc-1907	11	29	aikaterini	aikaterini	ADJ
dpc-1907	11	30	tsentemeidou	tsentemeidou	NOUN
dpc-1907	11	31	,	,	PUNCT
dpc-1907	11	32	ms	ms	PROPN
dpc-1907	11	33	.	.	PROPN
dpc-1907	11	34	first	first	PROPN
dpc-1907	11	35	department	department	PROPN
dpc-1907	11	36	of	of	ADP
dpc-1907	11	37	dermatology	dermatology	NOUN
dpc-1907	11	38	and	and	CCONJ
dpc-1907	11	39	venereology	venereology	NOUN
dpc-1907	11	40	,	,	PUNCT
dpc-1907	11	41	school	school	NOUN
dpc-1907	11	42	of	of	ADP
dpc-1907	11	43	medicine	medicine	NOUN
dpc-1907	11	44	,	,	PUNCT
dpc-1907	11	45	aristotle	aristotle	PROPN
dpc-1907	11	46	university	university	PROPN
dpc-1907	11	47	,	,	PUNCT
dpc-1907	11	48	thessaloniki	thessaloniki	PROPN
dpc-1907	11	49	,	,	PUNCT
dpc-1907	11	50	greece	greece	PROPN
dpc-1907	11	51	.	.	PUNCT
dpc-1907	12	1	email	email	NOUN
dpc-1907	12	2	:	:	PUNCT
dpc-1907	13	1	ktsenteme@gmail.com	ktsenteme@gmail.com	X
dpc-1907	13	2	introduction	introduction	NOUN
dpc-1907	13	3	:	:	PUNCT
dpc-1907	13	4	drug	drug	NOUN
dpc-1907	13	5	survival	survival	NOUN
dpc-1907	13	6	is	be	AUX
dpc-1907	13	7	an	an	DET
dpc-1907	13	8	indirect	indirect	ADJ
dpc-1907	13	9	measure	measure	NOUN
dpc-1907	13	10	of	of	ADP
dpc-1907	13	11	efficacy	efficacy	NOUN
dpc-1907	13	12	and	and	CCONJ
dpc-1907	13	13	safety	safety	NOUN
dpc-1907	13	14	and	and	CCONJ
dpc-1907	13	15	its	its	PRON
dpc-1907	13	16	post	post	ADJ
dpc-1907	13	17	-	-	ADJ
dpc-1907	13	18	marketing	marketing	ADJ
dpc-1907	13	19	assessment	assessment	NOUN
dpc-1907	13	20	using	use	VERB
dpc-1907	13	21	real	real	ADJ
dpc-1907	13	22	-	-	PUNCT
dpc-1907	13	23	life	life	NOUN
dpc-1907	13	24	data	datum	NOUN
dpc-1907	13	25	is	be	AUX
dpc-1907	13	26	invaluable	invaluable	ADJ
dpc-1907	13	27	.	.	PUNCT
dpc-1907	14	1	objectives	objective	NOUN
dpc-1907	14	2	:	:	PUNCT
dpc-1907	14	3	to	to	PART
dpc-1907	14	4	investigate	investigate	VERB
dpc-1907	14	5	the	the	DET
dpc-1907	14	6	survival	survival	NOUN
dpc-1907	14	7	of	of	ADP
dpc-1907	14	8	apremilast	apremilast	NOUN
dpc-1907	14	9	in	in	ADP
dpc-1907	14	10	a	a	DET
dpc-1907	14	11	cohort	cohort	NOUN
dpc-1907	14	12	of	of	ADP
dpc-1907	14	13	psoriasis	psoriasis	NOUN
dpc-1907	14	14	patients	patient	NOUN
dpc-1907	14	15	treated	treat	VERB
dpc-1907	14	16	with	with	ADP
dpc-1907	14	17	apremilast	apremilast	NOUN
dpc-1907	14	18	in	in	ADP
dpc-1907	14	19	a	a	DET
dpc-1907	14	20	greek	greek	ADJ
dpc-1907	14	21	hospital	hospital	NOUN
dpc-1907	14	22	.	.	PUNCT
dpc-1907	15	1	methods	method	NOUN
dpc-1907	15	2	:	:	PUNCT
dpc-1907	15	3	a	a	DET
dpc-1907	15	4	retrospective	retrospective	ADJ
dpc-1907	15	5	cross	cross	ADJ
dpc-1907	15	6	-	-	ADJ
dpc-1907	15	7	sectional	sectional	ADJ
dpc-1907	15	8	study	study	NOUN
dpc-1907	15	9	examined	examine	VERB
dpc-1907	15	10	adult	adult	NOUN
dpc-1907	15	11	psoriasis	psoriasis	NOUN
dpc-1907	15	12	patients	patient	NOUN
dpc-1907	15	13	receiving	receive	VERB
dpc-1907	15	14	apremilast	apremilast	NOUN
dpc-1907	15	15	(	(	PUNCT
dpc-1907	15	16	march	march	PROPN
dpc-1907	15	17	2016	2016	NUM
dpc-1907	15	18	to	to	ADP
dpc-1907	15	19	january	january	PROPN
dpc-1907	15	20	2021	2021	NUM
dpc-1907	15	21	)	)	PUNCT
dpc-1907	15	22	.	.	PUNCT
dpc-1907	16	1	primary	primary	ADJ
dpc-1907	16	2	endpoint	endpoint	NOUN
dpc-1907	16	3	was	be	AUX
dpc-1907	16	4	the	the	DET
dpc-1907	16	5	cumulative	cumulative	ADJ
dpc-1907	16	6	survival	survival	NOUN
dpc-1907	16	7	probability	probability	NOUN
dpc-1907	16	8	at	at	ADP
dpc-1907	16	9	52	52	NUM
dpc-1907	16	10	weeks	week	NOUN
dpc-1907	16	11	.	.	PUNCT
dpc-1907	17	1	kaplan	kaplan	PROPN
dpc-1907	17	2	-	-	PUNCT
dpc-1907	17	3	meier	meier	PROPN
dpc-1907	17	4	analysis	analysis	NOUN
dpc-1907	17	5	was	be	AUX
dpc-1907	17	6	used	use	VERB
dpc-1907	17	7	to	to	PART
dpc-1907	17	8	calculate	calculate	VERB
dpc-1907	17	9	survival	survival	NOUN
dpc-1907	17	10	probability	probability	NOUN
dpc-1907	17	11	.	.	PUNCT
dpc-1907	18	1	cox	cox	PROPN
dpc-1907	18	2	regression	regression	PROPN
dpc-1907	18	3	analysis	analysis	NOUN
dpc-1907	18	4	was	be	AUX
dpc-1907	18	5	performed	perform	VERB
dpc-1907	18	6	to	to	PART
dpc-1907	18	7	investigate	investigate	VERB
dpc-1907	18	8	potential	potential	ADJ
dpc-1907	18	9	risk	risk	NOUN
dpc-1907	18	10	factors	factor	NOUN
dpc-1907	18	11	for	for	ADP
dpc-1907	18	12	apremilast	apremilast	ADJ
dpc-1907	18	13	discontinuation	discontinuation	NOUN
dpc-1907	18	14	.	.	PUNCT
dpc-1907	19	1	results	result	NOUN
dpc-1907	19	2	:	:	PUNCT
dpc-1907	19	3	one	one	NUM
dpc-1907	19	4	hundred	hundred	NUM
dpc-1907	19	5	and	and	CCONJ
dpc-1907	19	6	two	two	NUM
dpc-1907	19	7	patients	patient	NOUN
dpc-1907	19	8	(	(	PUNCT
dpc-1907	19	9	29.4	29.4	NUM
dpc-1907	19	10	%	%	NOUN
dpc-1907	19	11	females	female	NOUN
dpc-1907	19	12	)	)	PUNCT
dpc-1907	19	13	with	with	ADP
dpc-1907	19	14	a	a	DET
dpc-1907	19	15	mean	mean	ADJ
dpc-1907	19	16	age	age	NOUN
dpc-1907	19	17	of	of	ADP
dpc-1907	19	18	55.9	55.9	NUM
dpc-1907	19	19	years	year	NOUN
dpc-1907	19	20	(	(	PUNCT
dpc-1907	19	21	standard	standard	ADJ
dpc-1907	19	22	deviation	deviation	NOUN
dpc-1907	19	23	15.21	15.21	NUM
dpc-1907	19	24	)	)	PUNCT
dpc-1907	19	25	were	be	AUX
dpc-1907	19	26	included	include	VERB
dpc-1907	19	27	.	.	PUNCT
dpc-1907	20	1	sixty	sixty	NUM
dpc-1907	20	2	-	-	PUNCT
dpc-1907	20	3	five	five	NUM
dpc-1907	20	4	patients	patient	NOUN
dpc-1907	20	5	(	(	PUNCT
dpc-1907	20	6	63.7	63.7	NUM
dpc-1907	20	7	%	%	NOUN
dpc-1907	20	8	)	)	PUNCT
dpc-1907	20	9	had	have	AUX
dpc-1907	20	10	discontinued	discontinue	VERB
dpc-1907	20	11	treatment	treatment	NOUN
dpc-1907	20	12	by	by	ADP
dpc-1907	20	13	lock	lock	NOUN
dpc-1907	20	14	date	date	NOUN
dpc-1907	20	15	:	:	PUNCT
dpc-1907	20	16	19	19	NUM
dpc-1907	20	17	(	(	PUNCT
dpc-1907	20	18	18.6	18.6	NUM
dpc-1907	20	19	%	%	NOUN
dpc-1907	20	20	)	)	PUNCT
dpc-1907	20	21	due	due	ADP
dpc-1907	20	22	to	to	ADP
dpc-1907	20	23	lack	lack	NOUN
dpc-1907	20	24	of	of	ADP
dpc-1907	20	25	efficacy	efficacy	NOUN
dpc-1907	20	26	,	,	PUNCT
dpc-1907	20	27	24	24	NUM
dpc-1907	20	28	(	(	PUNCT
dpc-1907	20	29	23.5	23.5	NUM
dpc-1907	20	30	%	%	NOUN
dpc-1907	20	31	)	)	PUNCT
dpc-1907	20	32	due	due	ADP
dpc-1907	20	33	to	to	ADP
dpc-1907	20	34	loss	loss	NOUN
dpc-1907	20	35	of	of	ADP
dpc-1907	20	36	efficacy	efficacy	NOUN
dpc-1907	20	37	,	,	PUNCT
dpc-1907	20	38	15	15	NUM
dpc-1907	20	39	(	(	PUNCT
dpc-1907	20	40	14.7	14.7	NUM
dpc-1907	20	41	%	%	NOUN
dpc-1907	20	42	)	)	PUNCT
dpc-1907	20	43	due	due	ADP
dpc-1907	20	44	to	to	ADP
dpc-1907	20	45	adverse	adverse	ADJ
dpc-1907	20	46	reactions	reaction	NOUN
dpc-1907	20	47	,	,	PUNCT
dpc-1907	20	48	and	and	CCONJ
dpc-1907	20	49	7	7	NUM
dpc-1907	20	50	(	(	PUNCT
dpc-1907	20	51	6.9	6.9	NUM
dpc-1907	20	52	%	%	NOUN
dpc-1907	20	53	)	)	PUNCT
dpc-1907	20	54	due	due	ADP
dpc-1907	20	55	to	to	ADP
dpc-1907	20	56	other	other	ADJ
dpc-1907	20	57	reasons	reason	NOUN
dpc-1907	20	58	.	.	PUNCT
dpc-1907	21	1	cumulative	cumulative	ADJ
dpc-1907	21	2	survival	survival	NOUN
dpc-1907	21	3	probability	probability	NOUN
dpc-1907	21	4	at	at	ADP
dpc-1907	21	5	52	52	NUM
dpc-1907	21	6	weeks	week	NOUN
dpc-1907	21	7	was	be	AUX
dpc-1907	21	8	52.1	52.1	NUM
dpc-1907	21	9	%	%	NOUN
dpc-1907	21	10	.	.	PUNCT
dpc-1907	22	1	median	median	ADJ
dpc-1907	22	2	survival	survival	NOUN
dpc-1907	22	3	time	time	NOUN
dpc-1907	22	4	for	for	ADP
dpc-1907	22	5	all	all	DET
dpc-1907	22	6	reasons	reason	NOUN
dpc-1907	22	7	for	for	ADP
dpc-1907	22	8	discontinuation	discontinuation	NOUN
dpc-1907	22	9	was	be	AUX
dpc-1907	22	10	58	58	NUM
dpc-1907	22	11	weeks	week	NOUN
dpc-1907	22	12	(	(	PUNCT
dpc-1907	22	13	95	95	NUM
dpc-1907	22	14	%	%	NOUN
dpc-1907	22	15	confidence	confidence	NOUN
dpc-1907	22	16	interval	interval	NOUN
dpc-1907	22	17	40.02	40.02	NUM
dpc-1907	22	18	,	,	PUNCT
dpc-1907	22	19	75.98	75.98	NUM
dpc-1907	22	20	)	)	PUNCT
dpc-1907	22	21	.	.	PUNCT
dpc-1907	23	1	conclusions	conclusion	NOUN
dpc-1907	23	2	:	:	PUNCT
dpc-1907	23	3	approximately	approximately	ADV
dpc-1907	23	4	half	half	NOUN
dpc-1907	23	5	of	of	ADP
dpc-1907	23	6	patients	patient	NOUN
dpc-1907	23	7	remained	remain	VERB
dpc-1907	23	8	on	on	ADP
dpc-1907	23	9	apremilast	apremilast	ADV
dpc-1907	23	10	after	after	ADP
dpc-1907	23	11	1	1	NUM
dpc-1907	23	12	year	year	NOUN
dpc-1907	23	13	of	of	ADP
dpc-1907	23	14	treatment	treatment	NOUN
dpc-1907	23	15	.	.	PUNCT
dpc-1907	24	1	secondary	secondary	ADJ
dpc-1907	24	2	drug	drug	NOUN
dpc-1907	24	3	failure	failure	NOUN
dpc-1907	24	4	was	be	AUX
dpc-1907	24	5	the	the	DET
dpc-1907	24	6	most	most	ADV
dpc-1907	24	7	common	common	ADJ
dpc-1907	24	8	reason	reason	NOUN
dpc-1907	24	9	for	for	ADP
dpc-1907	24	10	discontinuation	discontinuation	NOUN
dpc-1907	24	11	.	.	PUNCT
dpc-1907	25	1	abstract	abstract	ADJ
dpc-1907	25	2	2	2	NUM
dpc-1907	25	3	original	original	ADJ
dpc-1907	25	4	article	article	NOUN
dpc-1907	25	5	|	|	ADV
dpc-1907	25	6	dermatol	dermatol	ADJ
dpc-1907	25	7	pract	pract	NOUN
dpc-1907	25	8	concept	concept	NOUN
dpc-1907	25	9	.	.	PUNCT
dpc-1907	26	1	2022;12(2):e2022076	2022;12(2):e2022076	NUM
dpc-1907	26	2	introduction	introduction	NOUN
dpc-1907	26	3	apremilast	apremilast	NOUN
dpc-1907	26	4	(	(	PUNCT
dpc-1907	26	5	otezla	otezla	PROPN
dpc-1907	26	6	®	®	PROPN
dpc-1907	26	7	,	,	PUNCT
dpc-1907	26	8	amgen	amgen	PROPN
dpc-1907	26	9	)	)	PUNCT
dpc-1907	26	10	is	be	AUX
dpc-1907	26	11	an	an	DET
dpc-1907	26	12	orally	orally	ADV
dpc-1907	26	13	administered	administer	VERB
dpc-1907	26	14	pde4	pde4	NOUN
dpc-1907	26	15	inhibitor	inhibitor	NOUN
dpc-1907	26	16	,	,	PUNCT
dpc-1907	26	17	whose	whose	DET
dpc-1907	26	18	efficacy	efficacy	NOUN
dpc-1907	26	19	and	and	CCONJ
dpc-1907	26	20	tolerability	tolerability	NOUN
dpc-1907	26	21	for	for	ADP
dpc-1907	26	22	the	the	DET
dpc-1907	26	23	treatment	treatment	NOUN
dpc-1907	26	24	of	of	ADP
dpc-1907	26	25	moderate	moderate	ADJ
dpc-1907	26	26	-	-	PUNCT
dpc-1907	26	27	to	to	ADP
dpc-1907	26	28	-	-	PUNCT
dpc-1907	26	29	severe	severe	ADJ
dpc-1907	26	30	plaque	plaque	NOUN
dpc-1907	26	31	psoriasis	psoriasis	NOUN
dpc-1907	26	32	was	be	AUX
dpc-1907	26	33	investigated	investigate	VERB
dpc-1907	26	34	in	in	ADP
dpc-1907	26	35	the	the	DET
dpc-1907	26	36	esteem	esteem	NOUN
dpc-1907	26	37	phase	phase	NOUN
dpc-1907	26	38	iii	iii	NUM
dpc-1907	26	39	trials	trial	NOUN
dpc-1907	26	40	[	[	X
dpc-1907	26	41	1,2	1,2	NUM
dpc-1907	26	42	]	]	PUNCT
dpc-1907	26	43	.	.	PUNCT
dpc-1907	27	1	psoriasis	psoriasis	NOUN
dpc-1907	27	2	treatment	treatment	NOUN
dpc-1907	27	3	with	with	ADP
dpc-1907	27	4	biologics	biologic	NOUN
dpc-1907	27	5	and	and	CCONJ
dpc-1907	27	6	small	small	ADJ
dpc-1907	27	7	-	-	PUNCT
dpc-1907	27	8	molecule	molecule	NOUN
dpc-1907	27	9	agents	agent	NOUN
dpc-1907	27	10	is	be	AUX
dpc-1907	27	11	of	of	ADP
dpc-1907	27	12	finite	finite	ADJ
dpc-1907	27	13	duration	duration	NOUN
dpc-1907	27	14	,	,	PUNCT
dpc-1907	27	15	most	most	ADV
dpc-1907	27	16	often	often	ADV
dpc-1907	27	17	due	due	ADJ
dpc-1907	27	18	to	to	ADP
dpc-1907	27	19	efficacy	efficacy	NOUN
dpc-1907	27	20	-	-	PUNCT
dpc-1907	27	21	related	relate	VERB
dpc-1907	27	22	reasons	reason	NOUN
dpc-1907	27	23	[	[	X
dpc-1907	27	24	3	3	X
dpc-1907	27	25	]	]	PUNCT
dpc-1907	27	26	the	the	DET
dpc-1907	27	27	probability	probability	NOUN
dpc-1907	27	28	that	that	SCONJ
dpc-1907	27	29	psoriasis	psoriasis	NOUN
dpc-1907	27	30	patients	patient	NOUN
dpc-1907	27	31	will	will	AUX
dpc-1907	27	32	stay	stay	VERB
dpc-1907	27	33	on	on	ADP
dpc-1907	27	34	a	a	DET
dpc-1907	27	35	biologic	biologic	ADJ
dpc-1907	27	36	treatment	treatment	NOUN
dpc-1907	27	37	for	for	ADP
dpc-1907	27	38	≥3	≥3	PROPN
dpc-1907	27	39	years	year	NOUN
dpc-1907	27	40	is	be	AUX
dpc-1907	27	41	53%-58	53%-58	NUM
dpc-1907	27	42	%	%	NOUN
dpc-1907	27	43	[	[	X
dpc-1907	27	44	4	4	NUM
dpc-1907	27	45	]	]	PUNCT
dpc-1907	27	46	.	.	PUNCT
dpc-1907	28	1	anti	anti	ADJ
dpc-1907	28	2	-	-	ADJ
dpc-1907	28	3	drug	drug	ADJ
dpc-1907	28	4	antibodies	antibody	NOUN
dpc-1907	28	5	,	,	PUNCT
dpc-1907	28	6	genomic	genomic	NOUN
dpc-1907	28	7	and	and	CCONJ
dpc-1907	28	8	transcriptomic	transcriptomic	ADJ
dpc-1907	28	9	parameters	parameter	NOUN
dpc-1907	28	10	as	as	ADV
dpc-1907	28	11	well	well	ADV
dpc-1907	28	12	as	as	ADP
dpc-1907	28	13	non	non	ADJ
dpc-1907	28	14	-	-	NOUN
dpc-1907	28	15	compliance	compliance	NOUN
dpc-1907	28	16	could	could	AUX
dpc-1907	28	17	possibly	possibly	ADV
dpc-1907	28	18	explain	explain	VERB
dpc-1907	28	19	this	this	DET
dpc-1907	28	20	phenomenon	phenomenon	NOUN
dpc-1907	28	21	[	[	X
dpc-1907	28	22	4,5	4,5	NUM
dpc-1907	28	23	]	]	PUNCT
dpc-1907	28	24	.	.	PUNCT
dpc-1907	29	1	forty	forty	NUM
dpc-1907	29	2	-	-	PUNCT
dpc-1907	29	3	five	five	NUM
dpc-1907	29	4	of	of	ADP
dpc-1907	29	5	382	382	NUM
dpc-1907	29	6	(	(	PUNCT
dpc-1907	29	7	11.78	11.78	NUM
dpc-1907	29	8	%	%	NOUN
dpc-1907	29	9	)	)	PUNCT
dpc-1907	29	10	esteem	esteem	NOUN
dpc-1907	29	11	2	2	NUM
dpc-1907	29	12	participants	participant	NOUN
dpc-1907	29	13	,	,	PUNCT
dpc-1907	29	14	who	who	PRON
dpc-1907	29	15	received	receive	VERB
dpc-1907	29	16	apremilast	apremilast	ADJ
dpc-1907	29	17	,	,	PUNCT
dpc-1907	29	18	discontinued	discontinued	ADJ
dpc-1907	29	19	treatment	treatment	NOUN
dpc-1907	29	20	due	due	ADP
dpc-1907	29	21	to	to	ADP
dpc-1907	29	22	lack	lack	NOUN
dpc-1907	29	23	of	of	ADP
dpc-1907	29	24	efficacy	efficacy	NOUN
dpc-1907	29	25	by	by	ADP
dpc-1907	29	26	week	week	NOUN
dpc-1907	29	27	52	52	NUM
dpc-1907	30	1	[	[	X
dpc-1907	30	2	2	2	NUM
dpc-1907	30	3	]	]	PUNCT
dpc-1907	30	4	.	.	PUNCT
dpc-1907	31	1	long	long	ADJ
dpc-1907	31	2	-	-	PUNCT
dpc-1907	31	3	term	term	NOUN
dpc-1907	31	4	(	(	PUNCT
dpc-1907	31	5	≥156	≥156	NOUN
dpc-1907	31	6	weeks	week	NOUN
dpc-1907	31	7	)	)	PUNCT
dpc-1907	31	8	pooled	pool	VERB
dpc-1907	31	9	data	datum	NOUN
dpc-1907	31	10	from	from	ADP
dpc-1907	31	11	the	the	DET
dpc-1907	31	12	two	two	NUM
dpc-1907	31	13	esteem	esteem	NOUN
dpc-1907	31	14	trials	trial	NOUN
dpc-1907	31	15	showed	show	VERB
dpc-1907	31	16	that	that	SCONJ
dpc-1907	31	17	34.7	34.7	NUM
dpc-1907	31	18	%	%	NOUN
dpc-1907	31	19	of	of	ADP
dpc-1907	31	20	participants	participant	NOUN
dpc-1907	31	21	receiving	receive	VERB
dpc-1907	31	22	apremilast	apremilast	NOUN
dpc-1907	31	23	discontinued	discontinue	VERB
dpc-1907	31	24	treatment	treatment	NOUN
dpc-1907	31	25	due	due	ADP
dpc-1907	31	26	to	to	ADP
dpc-1907	31	27	lack	lack	NOUN
dpc-1907	31	28	of	of	ADP
dpc-1907	31	29	efficacy	efficacy	NOUN
dpc-1907	31	30	,	,	PUNCT
dpc-1907	31	31	which	which	PRON
dpc-1907	31	32	was	be	AUX
dpc-1907	31	33	the	the	DET
dpc-1907	31	34	most	most	ADV
dpc-1907	31	35	common	common	ADJ
dpc-1907	31	36	reason	reason	NOUN
dpc-1907	31	37	for	for	ADP
dpc-1907	31	38	treatment	treatment	NOUN
dpc-1907	31	39	cessation	cessation	NOUN
dpc-1907	31	40	[	[	X
dpc-1907	31	41	6	6	NUM
dpc-1907	31	42	]	]	PUNCT
dpc-1907	31	43	.	.	PUNCT
dpc-1907	32	1	drug	drug	NOUN
dpc-1907	32	2	survival	survival	NOUN
dpc-1907	32	3	–	–	PUNCT
dpc-1907	32	4	time	time	NOUN
dpc-1907	32	5	from	from	ADP
dpc-1907	32	6	initiation	initiation	NOUN
dpc-1907	32	7	to	to	ADP
dpc-1907	32	8	discontinuation	discontinuation	NOUN
dpc-1907	32	9	of	of	ADP
dpc-1907	32	10	treatment	treatment	NOUN
dpc-1907	32	11	–	–	PUNCT
dpc-1907	32	12	can	can	AUX
dpc-1907	32	13	be	be	AUX
dpc-1907	32	14	used	use	VERB
dpc-1907	32	15	as	as	ADP
dpc-1907	32	16	a	a	DET
dpc-1907	32	17	surrogate	surrogate	ADJ
dpc-1907	32	18	measure	measure	NOUN
dpc-1907	32	19	for	for	ADP
dpc-1907	32	20	drug	drug	NOUN
dpc-1907	32	21	efficacy	efficacy	NOUN
dpc-1907	32	22	and	and	CCONJ
dpc-1907	32	23	tolerability	tolerability	NOUN
dpc-1907	32	24	[	[	X
dpc-1907	32	25	4	4	NUM
dpc-1907	32	26	]	]	PUNCT
dpc-1907	32	27	.	.	PUNCT
dpc-1907	33	1	as	as	SCONJ
dpc-1907	33	2	everyday	everyday	ADJ
dpc-1907	33	3	practice	practice	NOUN
dpc-1907	33	4	may	may	AUX
dpc-1907	33	5	differ	differ	VERB
dpc-1907	33	6	from	from	ADP
dpc-1907	33	7	the	the	DET
dpc-1907	33	8	setting	setting	NOUN
dpc-1907	33	9	of	of	ADP
dpc-1907	33	10	clinical	clinical	ADJ
dpc-1907	33	11	trials	trial	NOUN
dpc-1907	33	12	,	,	PUNCT
dpc-1907	33	13	real	real	ADJ
dpc-1907	33	14	-	-	PUNCT
dpc-1907	33	15	world	world	NOUN
dpc-1907	33	16	data	datum	NOUN
dpc-1907	33	17	is	be	AUX
dpc-1907	33	18	invaluable	invaluable	ADJ
dpc-1907	33	19	.	.	PUNCT
dpc-1907	34	1	objectives	objective	NOUN
dpc-1907	34	2	this	this	DET
dpc-1907	34	3	study	study	NOUN
dpc-1907	34	4	was	be	AUX
dpc-1907	34	5	conducted	conduct	VERB
dpc-1907	34	6	to	to	PART
dpc-1907	34	7	investigate	investigate	VERB
dpc-1907	34	8	the	the	DET
dpc-1907	34	9	survival	survival	NOUN
dpc-1907	34	10	of	of	ADP
dpc-1907	34	11	apremilast	apremilast	NOUN
dpc-1907	34	12	in	in	ADP
dpc-1907	34	13	a	a	DET
dpc-1907	34	14	cohort	cohort	NOUN
dpc-1907	34	15	of	of	ADP
dpc-1907	34	16	patients	patient	NOUN
dpc-1907	34	17	treated	treat	VERB
dpc-1907	34	18	for	for	ADP
dpc-1907	34	19	psoriasis	psoriasis	NOUN
dpc-1907	34	20	in	in	ADP
dpc-1907	34	21	a	a	DET
dpc-1907	34	22	real	real	ADJ
dpc-1907	34	23	clinical	clinical	ADJ
dpc-1907	34	24	setting	setting	NOUN
dpc-1907	34	25	.	.	PUNCT
dpc-1907	35	1	methods	method	NOUN
dpc-1907	35	2	a	a	DET
dpc-1907	35	3	retrospective	retrospective	ADJ
dpc-1907	35	4	cross	cross	ADJ
dpc-1907	35	5	-	-	ADJ
dpc-1907	35	6	sectional	sectional	ADJ
dpc-1907	35	7	study	study	NOUN
dpc-1907	35	8	was	be	AUX
dpc-1907	35	9	performed	perform	VERB
dpc-1907	35	10	.	.	PUNCT
dpc-1907	36	1	data	datum	NOUN
dpc-1907	36	2	was	be	AUX
dpc-1907	36	3	retrieved	retrieve	VERB
dpc-1907	36	4	from	from	ADP
dpc-1907	36	5	the	the	DET
dpc-1907	36	6	psoriasis	psoriasis	NOUN
dpc-1907	36	7	archives	archive	NOUN
dpc-1907	36	8	of	of	ADP
dpc-1907	36	9	the	the	DET
dpc-1907	36	10	1st	1st	ADJ
dpc-1907	36	11	dermatology	dermatology	NOUN
dpc-1907	36	12	department	department	NOUN
dpc-1907	36	13	,	,	PUNCT
dpc-1907	36	14	aristotle	aristotle	PROPN
dpc-1907	36	15	university	university	PROPN
dpc-1907	36	16	,	,	PUNCT
dpc-1907	36	17	thessaloniki	thessaloniki	PROPN
dpc-1907	36	18	,	,	PUNCT
dpc-1907	36	19	greece	greece	PROPN
dpc-1907	36	20	.	.	PUNCT
dpc-1907	37	1	all	all	DET
dpc-1907	37	2	adult	adult	NOUN
dpc-1907	37	3	patients	patient	NOUN
dpc-1907	37	4	with	with	ADP
dpc-1907	37	5	any	any	DET
dpc-1907	37	6	type	type	NOUN
dpc-1907	37	7	of	of	ADP
dpc-1907	37	8	psoriasis	psoriasis	NOUN
dpc-1907	37	9	,	,	PUNCT
dpc-1907	37	10	who	who	PRON
dpc-1907	37	11	had	have	AUX
dpc-1907	37	12	received	receive	VERB
dpc-1907	37	13	at	at	ADV
dpc-1907	37	14	least	least	ADV
dpc-1907	37	15	one	one	NUM
dpc-1907	37	16	dose	dose	NOUN
dpc-1907	37	17	of	of	ADP
dpc-1907	37	18	apremilast	apremilast	NOUN
dpc-1907	37	19	from	from	ADP
dpc-1907	37	20	march	march	PROPN
dpc-1907	37	21	2016	2016	NUM
dpc-1907	37	22	until	until	ADP
dpc-1907	37	23	january	january	PROPN
dpc-1907	37	24	2021	2021	NUM
dpc-1907	37	25	,	,	PUNCT
dpc-1907	37	26	were	be	AUX
dpc-1907	37	27	eligible	eligible	ADJ
dpc-1907	37	28	for	for	ADP
dpc-1907	37	29	inclusion	inclusion	NOUN
dpc-1907	37	30	in	in	ADP
dpc-1907	37	31	the	the	DET
dpc-1907	37	32	study	study	NOUN
dpc-1907	37	33	.	.	PUNCT
dpc-1907	38	1	dosing	dose	VERB
dpc-1907	38	2	followed	follow	VERB
dpc-1907	38	3	summary	summary	NOUN
dpc-1907	38	4	of	of	ADP
dpc-1907	38	5	product	product	NOUN
dpc-1907	38	6	characteristics	characteristic	NOUN
dpc-1907	38	7	.	.	PUNCT
dpc-1907	39	1	primary	primary	ADJ
dpc-1907	39	2	endpoint	endpoint	NOUN
dpc-1907	39	3	was	be	AUX
dpc-1907	39	4	cumulative	cumulative	ADJ
dpc-1907	39	5	survival	survival	NOUN
dpc-1907	39	6	probability	probability	NOUN
dpc-1907	39	7	at	at	ADP
dpc-1907	39	8	52	52	NUM
dpc-1907	39	9	weeks	week	NOUN
dpc-1907	39	10	.	.	PUNCT
dpc-1907	40	1	secondary	secondary	ADJ
dpc-1907	40	2	endpoints	endpoint	NOUN
dpc-1907	40	3	were	be	AUX
dpc-1907	40	4	cumulative	cumulative	ADJ
dpc-1907	40	5	survival	survival	NOUN
dpc-1907	40	6	probability	probability	NOUN
dpc-1907	40	7	at	at	ADP
dpc-1907	40	8	weeks	week	NOUN
dpc-1907	40	9	24	24	NUM
dpc-1907	40	10	,	,	PUNCT
dpc-1907	40	11	104	104	NUM
dpc-1907	40	12	,	,	PUNCT
dpc-1907	40	13	156	156	NUM
dpc-1907	40	14	,	,	PUNCT
dpc-1907	40	15	and	and	CCONJ
dpc-1907	40	16	208	208	NUM
dpc-1907	40	17	,	,	PUNCT
dpc-1907	40	18	percentage	percentage	NOUN
dpc-1907	40	19	of	of	ADP
dpc-1907	40	20	patients	patient	NOUN
dpc-1907	40	21	achieving	achieve	VERB
dpc-1907	40	22	75	75	NUM
dpc-1907	40	23	%	%	NOUN
dpc-1907	40	24	reduction	reduction	NOUN
dpc-1907	40	25	in	in	ADP
dpc-1907	40	26	their	their	PRON
dpc-1907	40	27	baseline	baseline	ADJ
dpc-1907	40	28	psoriasis	psoriasis	NOUN
dpc-1907	40	29	area	area	NOUN
dpc-1907	40	30	severity	severity	NOUN
dpc-1907	40	31	index	index	NOUN
dpc-1907	40	32	(	(	PUNCT
dpc-1907	40	33	pasi	pasi	NOUN
dpc-1907	40	34	)	)	PUNCT
dpc-1907	40	35	score	score	NOUN
dpc-1907	40	36	(	(	PUNCT
dpc-1907	40	37	pasi75	pasi75	NOUN
dpc-1907	40	38	)	)	PUNCT
dpc-1907	40	39	at	at	ADP
dpc-1907	40	40	weeks	week	NOUN
dpc-1907	40	41	16	16	NUM
dpc-1907	40	42	,	,	PUNCT
dpc-1907	40	43	24	24	NUM
dpc-1907	40	44	,	,	PUNCT
dpc-1907	40	45	52	52	NUM
dpc-1907	40	46	,	,	PUNCT
dpc-1907	40	47	104	104	NUM
dpc-1907	40	48	and	and	CCONJ
dpc-1907	40	49	156	156	NUM
dpc-1907	40	50	as	as	ADV
dpc-1907	40	51	well	well	ADV
dpc-1907	40	52	as	as	ADP
dpc-1907	40	53	mean	mean	ADJ
dpc-1907	40	54	/	/	SYM
dpc-1907	40	55	median	median	ADJ
dpc-1907	40	56	drug	drug	NOUN
dpc-1907	40	57	survival	survival	NOUN
dpc-1907	40	58	for	for	ADP
dpc-1907	40	59	all	all	DET
dpc-1907	40	60	reasons	reason	NOUN
dpc-1907	40	61	for	for	ADP
dpc-1907	40	62	discontinuation	discontinuation	NOUN
dpc-1907	40	63	and	and	CCONJ
dpc-1907	40	64	stratified	stratify	VERB
dpc-1907	40	65	for	for	ADP
dpc-1907	40	66	specific	specific	ADJ
dpc-1907	40	67	reason	reason	NOUN
dpc-1907	40	68	(	(	PUNCT
dpc-1907	40	69	lack	lack	NOUN
dpc-1907	40	70	of	of	ADP
dpc-1907	40	71	and	and	CCONJ
dpc-1907	40	72	loss	loss	NOUN
dpc-1907	40	73	of	of	ADP
dpc-1907	40	74	efficacy	efficacy	NOUN
dpc-1907	40	75	,	,	PUNCT
dpc-1907	40	76	adverse	adverse	ADJ
dpc-1907	40	77	events	event	NOUN
dpc-1907	40	78	,	,	PUNCT
dpc-1907	40	79	other	other	ADJ
dpc-1907	40	80	)	)	PUNCT
dpc-1907	40	81	.	.	PUNCT
dpc-1907	41	1	gender	gender	NOUN
dpc-1907	41	2	,	,	PUNCT
dpc-1907	41	3	age	age	NOUN
dpc-1907	41	4	,	,	PUNCT
dpc-1907	41	5	body	body	NOUN
dpc-1907	41	6	mass	mass	NOUN
dpc-1907	41	7	index	index	NOUN
dpc-1907	41	8	(	(	PUNCT
dpc-1907	41	9	bmi	bmi	PROPN
dpc-1907	41	10	,	,	PUNCT
dpc-1907	41	11	kg	kg	PROPN
dpc-1907	41	12	/	/	SYM
dpc-1907	41	13	m2	m2	PROPN
dpc-1907	41	14	)	)	PUNCT
dpc-1907	41	15	,	,	PUNCT
dpc-1907	41	16	presence	presence	NOUN
dpc-1907	41	17	of	of	ADP
dpc-1907	41	18	scalp	scalp	NOUN
dpc-1907	41	19	and	and	CCONJ
dpc-1907	41	20	nail	nail	NOUN
dpc-1907	41	21	psoriasis	psoriasis	NOUN
dpc-1907	41	22	,	,	PUNCT
dpc-1907	41	23	presence	presence	NOUN
dpc-1907	41	24	of	of	ADP
dpc-1907	41	25	psoriatic	psoriatic	ADJ
dpc-1907	41	26	arthritis	arthritis	NOUN
dpc-1907	41	27	,	,	PUNCT
dpc-1907	41	28	diabetes	diabetes	NOUN
dpc-1907	41	29	,	,	PUNCT
dpc-1907	41	30	hyperlipidaemia	hyperlipidaemia	NOUN
dpc-1907	41	31	,	,	PUNCT
dpc-1907	41	32	hypertension	hypertension	NOUN
dpc-1907	41	33	and	and	CCONJ
dpc-1907	41	34	cardiovascular	cardiovascular	ADJ
dpc-1907	41	35	disease	disease	NOUN
dpc-1907	41	36	,	,	PUNCT
dpc-1907	41	37	as	as	ADV
dpc-1907	41	38	well	well	ADV
dpc-1907	41	39	as	as	ADP
dpc-1907	41	40	previous	previous	ADJ
dpc-1907	41	41	treatment	treatment	NOUN
dpc-1907	41	42	with	with	ADP
dpc-1907	41	43	biologics	biologic	NOUN
dpc-1907	41	44	were	be	AUX
dpc-1907	41	45	tested	test	VERB
dpc-1907	41	46	as	as	ADP
dpc-1907	41	47	potential	potential	ADJ
dpc-1907	41	48	predictors	predictor	NOUN
dpc-1907	41	49	for	for	ADP
dpc-1907	41	50	drug	drug	NOUN
dpc-1907	41	51	discontinuation	discontinuation	NOUN
dpc-1907	41	52	.	.	PUNCT
dpc-1907	42	1	treatment	treatment	NOUN
dpc-1907	42	2	was	be	AUX
dpc-1907	42	3	considered	consider	VERB
dpc-1907	42	4	discontinued	discontinue	VERB
dpc-1907	42	5	if	if	SCONJ
dpc-1907	42	6	patients	patient	NOUN
dpc-1907	42	7	stopped	stop	VERB
dpc-1907	42	8	receiving	receive	VERB
dpc-1907	42	9	apremilast	apremilast	ADJ
dpc-1907	42	10	tablets	tablet	NOUN
dpc-1907	42	11	.	.	PUNCT
dpc-1907	43	1	reasons	reason	NOUN
dpc-1907	43	2	for	for	ADP
dpc-1907	43	3	discontinuation	discontinuation	NOUN
dpc-1907	43	4	were	be	AUX
dpc-1907	43	5	primary	primary	ADJ
dpc-1907	43	6	drug	drug	NOUN
dpc-1907	43	7	failure	failure	NOUN
dpc-1907	43	8	(	(	PUNCT
dpc-1907	43	9	no	no	DET
dpc-1907	43	10	≥50	≥50	NUM
dpc-1907	43	11	%	%	NOUN
dpc-1907	43	12	improvement	improvement	NOUN
dpc-1907	43	13	in	in	ADP
dpc-1907	43	14	baseline	baseline	ADJ
dpc-1907	43	15	pasi	pasi	NOUN
dpc-1907	43	16	–	–	PUNCT
dpc-1907	43	17	pasi50	pasi50	NOUN
dpc-1907	43	18	–	–	PUNCT
dpc-1907	43	19	by	by	ADP
dpc-1907	43	20	week	week	NOUN
dpc-1907	43	21	24	24	NUM
dpc-1907	43	22	)	)	PUNCT
dpc-1907	43	23	,	,	PUNCT
dpc-1907	43	24	secondary	secondary	ADJ
dpc-1907	43	25	drug	drug	NOUN
dpc-1907	43	26	failure	failure	NOUN
dpc-1907	43	27	(	(	PUNCT
dpc-1907	43	28	loss	loss	NOUN
dpc-1907	43	29	of	of	ADP
dpc-1907	43	30	achieved	achieve	VERB
dpc-1907	43	31	efficacy	efficacy	NOUN
dpc-1907	43	32	at	at	ADP
dpc-1907	43	33	two	two	NUM
dpc-1907	43	34	consecutive	consecutive	ADJ
dpc-1907	43	35	visits	visit	NOUN
dpc-1907	43	36	)	)	PUNCT
dpc-1907	43	37	,	,	PUNCT
dpc-1907	43	38	adverse	adverse	ADJ
dpc-1907	43	39	events	event	NOUN
dpc-1907	43	40	and	and	CCONJ
dpc-1907	43	41	personal	personal	ADJ
dpc-1907	43	42	/	/	SYM
dpc-1907	43	43	other	other	ADJ
dpc-1907	43	44	reasons	reason	NOUN
dpc-1907	43	45	.	.	PUNCT
dpc-1907	44	1	patients	patient	NOUN
dpc-1907	44	2	lost	lose	VERB
dpc-1907	44	3	to	to	PART
dpc-1907	44	4	follow	follow	VERB
dpc-1907	44	5	-	-	PUNCT
dpc-1907	44	6	up	up	NOUN
dpc-1907	44	7	were	be	AUX
dpc-1907	44	8	considered	consider	VERB
dpc-1907	44	9	to	to	PART
dpc-1907	44	10	have	have	AUX
dpc-1907	44	11	discontinued	discontinue	VERB
dpc-1907	44	12	treatment	treatment	NOUN
dpc-1907	44	13	.	.	PUNCT
dpc-1907	45	1	sequential	sequential	ADJ
dpc-1907	45	2	recruitment	recruitment	NOUN
dpc-1907	45	3	of	of	ADP
dpc-1907	45	4	all	all	DET
dpc-1907	45	5	eligible	eligible	ADJ
dpc-1907	45	6	treated	treat	VERB
dpc-1907	45	7	patients	patient	NOUN
dpc-1907	45	8	was	be	AUX
dpc-1907	45	9	performed	perform	VERB
dpc-1907	45	10	to	to	PART
dpc-1907	45	11	limit	limit	VERB
dpc-1907	45	12	selection	selection	NOUN
dpc-1907	45	13	bias	bias	NOUN
dpc-1907	45	14	.	.	PUNCT
dpc-1907	46	1	the	the	DET
dpc-1907	46	2	study	study	NOUN
dpc-1907	46	3	protocol	protocol	NOUN
dpc-1907	46	4	adhered	adhere	VERB
dpc-1907	46	5	to	to	ADP
dpc-1907	46	6	the	the	DET
dpc-1907	46	7	declaration	declaration	NOUN
dpc-1907	46	8	of	of	ADP
dpc-1907	46	9	helsinki	helsinki	PROPN
dpc-1907	46	10	and	and	CCONJ
dpc-1907	46	11	was	be	AUX
dpc-1907	46	12	approved	approve	VERB
dpc-1907	46	13	by	by	ADP
dpc-1907	46	14	the	the	DET
dpc-1907	46	15	ethics	ethic	NOUN
dpc-1907	46	16	committee	committee	PROPN
dpc-1907	46	17	of	of	ADP
dpc-1907	46	18	the	the	DET
dpc-1907	46	19	first	first	ADJ
dpc-1907	46	20	dermatology	dermatology	NOUN
dpc-1907	46	21	department	department	NOUN
dpc-1907	46	22	,	,	PUNCT
dpc-1907	46	23	aristotle	aristotle	PROPN
dpc-1907	46	24	university	university	PROPN
dpc-1907	46	25	,	,	PUNCT
dpc-1907	46	26	thessaloniki	thessaloniki	PROPN
dpc-1907	46	27	,	,	PUNCT
dpc-1907	46	28	greece	greece	PROPN
dpc-1907	46	29	.	.	PROPN
dpc-1907	46	30	signed	sign	VERB
dpc-1907	46	31	informed	informed	ADJ
dpc-1907	46	32	consent	consent	NOUN
dpc-1907	46	33	was	be	AUX
dpc-1907	46	34	obtained	obtain	VERB
dpc-1907	46	35	by	by	ADP
dpc-1907	46	36	all	all	DET
dpc-1907	46	37	participating	participate	VERB
dpc-1907	46	38	patients	patient	NOUN
dpc-1907	46	39	.	.	PUNCT
dpc-1907	47	1	spss	spss	PROPN
dpc-1907	47	2	software	software	PROPN
dpc-1907	47	3	version	version	NOUN
dpc-1907	47	4	25	25	NUM
dpc-1907	47	5	(	(	PUNCT
dpc-1907	47	6	ibm	ibm	PROPN
dpc-1907	47	7	corp	corp	PROPN
dpc-1907	47	8	.	.	PROPN
dpc-1907	47	9	)	)	PUNCT
dpc-1907	47	10	was	be	AUX
dpc-1907	47	11	used	use	VERB
dpc-1907	47	12	to	to	PART
dpc-1907	47	13	perform	perform	VERB
dpc-1907	47	14	all	all	DET
dpc-1907	47	15	statistical	statistical	ADJ
dpc-1907	47	16	analyses	analysis	NOUN
dpc-1907	47	17	.	.	PUNCT
dpc-1907	48	1	qualitative	qualitative	ADJ
dpc-1907	48	2	variables	variable	NOUN
dpc-1907	48	3	were	be	AUX
dpc-1907	48	4	described	describe	VERB
dpc-1907	48	5	through	through	ADP
dpc-1907	48	6	relative	relative	ADJ
dpc-1907	48	7	frequencies	frequency	NOUN
dpc-1907	48	8	.	.	PUNCT
dpc-1907	49	1	we	we	PRON
dpc-1907	49	2	used	use	VERB
dpc-1907	49	3	shapiro	shapiro	PROPN
dpc-1907	49	4	-	-	PUNCT
dpc-1907	49	5	wilk	wilk	NOUN
dpc-1907	49	6	test	test	NOUN
dpc-1907	49	7	to	to	PART
dpc-1907	49	8	check	check	VERB
dpc-1907	49	9	for	for	ADP
dpc-1907	49	10	normal	normal	ADJ
dpc-1907	49	11	distribution	distribution	NOUN
dpc-1907	49	12	of	of	ADP
dpc-1907	49	13	quantitative	quantitative	ADJ
dpc-1907	49	14	variables	variable	NOUN
dpc-1907	49	15	.	.	PUNCT
dpc-1907	50	1	mean	mean	VERB
dpc-1907	50	2	,	,	PUNCT
dpc-1907	50	3	standard	standard	ADJ
dpc-1907	50	4	deviation	deviation	NOUN
dpc-1907	50	5	(	(	PUNCT
dpc-1907	50	6	sd	sd	NOUN
dpc-1907	50	7	)	)	PUNCT
dpc-1907	50	8	and	and	CCONJ
dpc-1907	50	9	95	95	NUM
dpc-1907	50	10	%	%	NOUN
dpc-1907	50	11	confidence	confidence	NOUN
dpc-1907	50	12	interval	interval	NOUN
dpc-1907	50	13	(	(	PUNCT
dpc-1907	50	14	ci	ci	NOUN
dpc-1907	50	15	)	)	PUNCT
dpc-1907	50	16	were	be	AUX
dpc-1907	50	17	used	use	VERB
dpc-1907	50	18	in	in	ADP
dpc-1907	50	19	case	case	NOUN
dpc-1907	50	20	of	of	ADP
dpc-1907	50	21	normal	normal	ADJ
dpc-1907	50	22	distribution	distribution	NOUN
dpc-1907	50	23	,	,	PUNCT
dpc-1907	50	24	whereas	whereas	SCONJ
dpc-1907	50	25	median	median	ADJ
dpc-1907	50	26	and	and	CCONJ
dpc-1907	50	27	interquartile	interquartile	ADJ
dpc-1907	50	28	range	range	NOUN
dpc-1907	50	29	were	be	AUX
dpc-1907	50	30	used	use	VERB
dpc-1907	50	31	in	in	ADP
dpc-1907	50	32	the	the	DET
dpc-1907	50	33	opposite	opposite	ADJ
dpc-1907	50	34	case	case	NOUN
dpc-1907	50	35	.	.	PUNCT
dpc-1907	51	1	a	a	DET
dpc-1907	51	2	two	two	NUM
dpc-1907	51	3	-	-	PUNCT
dpc-1907	51	4	tailed	tail	VERB
dpc-1907	51	5	significance	significance	NOUN
dpc-1907	51	6	level	level	NOUN
dpc-1907	51	7	of	of	ADP
dpc-1907	51	8	<	<	NOUN
dpc-1907	51	9	0.05	0.05	NUM
dpc-1907	51	10	was	be	AUX
dpc-1907	51	11	set	set	VERB
dpc-1907	51	12	.	.	PUNCT
dpc-1907	52	1	kaplan	kaplan	PROPN
dpc-1907	52	2	-	-	PUNCT
dpc-1907	52	3	meier	meier	PROPN
dpc-1907	52	4	analysis	analysis	NOUN
dpc-1907	52	5	was	be	AUX
dpc-1907	52	6	used	use	VERB
dpc-1907	52	7	to	to	PART
dpc-1907	52	8	calculate	calculate	VERB
dpc-1907	52	9	survival	survival	NOUN
dpc-1907	52	10	probability	probability	PROPN
dpc-1907	52	11	.	.	PUNCT
dpc-1907	53	1	study	study	NOUN
dpc-1907	53	2	event	event	NOUN
dpc-1907	53	3	was	be	AUX
dpc-1907	53	4	drug	drug	NOUN
dpc-1907	53	5	discontinuation	discontinuation	NOUN
dpc-1907	53	6	due	due	ADP
dpc-1907	53	7	to	to	ADP
dpc-1907	53	8	any	any	DET
dpc-1907	53	9	reason	reason	NOUN
dpc-1907	53	10	or	or	CCONJ
dpc-1907	53	11	loss	loss	NOUN
dpc-1907	53	12	to	to	PART
dpc-1907	53	13	follow	follow	VERB
dpc-1907	53	14	-	-	PUNCT
dpc-1907	53	15	up	up	NOUN
dpc-1907	53	16	.	.	PUNCT
dpc-1907	54	1	patients	patient	NOUN
dpc-1907	54	2	still	still	ADV
dpc-1907	54	3	on	on	ADP
dpc-1907	54	4	treatment	treatment	NOUN
dpc-1907	54	5	were	be	AUX
dpc-1907	54	6	censored	censor	VERB
dpc-1907	54	7	at	at	ADP
dpc-1907	54	8	the	the	DET
dpc-1907	54	9	last	last	ADJ
dpc-1907	54	10	available	available	ADJ
dpc-1907	54	11	follow	follow	VERB
dpc-1907	54	12	-	-	PUNCT
dpc-1907	54	13	up	up	ADP
dpc-1907	54	14	visit	visit	NOUN
dpc-1907	54	15	.	.	PUNCT
dpc-1907	55	1	univariate	univariate	ADJ
dpc-1907	55	2	and	and	CCONJ
dpc-1907	55	3	multivariate	multivariate	VERB
dpc-1907	55	4	cox	cox	PROPN
dpc-1907	55	5	regression	regression	NOUN
dpc-1907	55	6	analysis	analysis	NOUN
dpc-1907	55	7	were	be	AUX
dpc-1907	55	8	performed	perform	VERB
dpc-1907	55	9	to	to	PART
dpc-1907	55	10	investigate	investigate	VERB
dpc-1907	55	11	potential	potential	ADJ
dpc-1907	55	12	risk	risk	NOUN
dpc-1907	55	13	factors	factor	NOUN
dpc-1907	55	14	for	for	ADP
dpc-1907	55	15	apremilast	apremilast	ADJ
dpc-1907	55	16	discontinuation	discontinuation	NOUN
dpc-1907	55	17	(	(	PUNCT
dpc-1907	55	18	hazard	hazard	NOUN
dpc-1907	55	19	ratio	ratio	NOUN
dpc-1907	55	20	,	,	PUNCT
dpc-1907	55	21	significance	significance	NOUN
dpc-1907	55	22	level	level	NOUN
dpc-1907	55	23	set	set	VERB
dpc-1907	55	24	at	at	ADP
dpc-1907	55	25	p	p	NOUN
dpc-1907	55	26	≤0.05	≤0.05	NOUN
dpc-1907	55	27	)	)	PUNCT
dpc-1907	55	28	.	.	PUNCT
dpc-1907	56	1	akaike	akaike	ADJ
dpc-1907	56	2	information	information	NOUN
dpc-1907	56	3	criterion	criterion	NOUN
dpc-1907	56	4	was	be	AUX
dpc-1907	56	5	used	use	VERB
dpc-1907	56	6	to	to	PART
dpc-1907	56	7	choose	choose	VERB
dpc-1907	56	8	the	the	DET
dpc-1907	56	9	best	well	ADV
dpc-1907	56	10	-	-	PUNCT
dpc-1907	56	11	fitting	fit	VERB
dpc-1907	56	12	model	model	NOUN
dpc-1907	56	13	for	for	ADP
dpc-1907	56	14	survival	survival	NOUN
dpc-1907	56	15	prediction	prediction	NOUN
dpc-1907	56	16	.	.	PUNCT
dpc-1907	57	1	results	result	VERB
dpc-1907	57	2	out	out	ADP
dpc-1907	57	3	of	of	ADP
dpc-1907	57	4	2313	2313	NUM
dpc-1907	57	5	psoriasis	psoriasis	NOUN
dpc-1907	57	6	patients	patient	NOUN
dpc-1907	57	7	registered	register	VERB
dpc-1907	57	8	in	in	ADP
dpc-1907	57	9	the	the	DET
dpc-1907	57	10	psoriasis	psoriasis	NOUN
dpc-1907	57	11	archives	archive	NOUN
dpc-1907	57	12	,	,	PUNCT
dpc-1907	57	13	110	110	NUM
dpc-1907	57	14	patients	patient	NOUN
dpc-1907	57	15	were	be	AUX
dpc-1907	57	16	potentially	potentially	ADV
dpc-1907	57	17	eligible	eligible	ADJ
dpc-1907	57	18	for	for	ADP
dpc-1907	57	19	inclusion	inclusion	NOUN
dpc-1907	57	20	.	.	PUNCT
dpc-1907	58	1	six	six	NUM
dpc-1907	58	2	take	take	VERB
dpc-1907	58	3	-	-	PUNCT
dpc-1907	58	4	home	home	NOUN
dpc-1907	58	5	message	message	NOUN
dpc-1907	58	6	•	•	NOUN
dpc-1907	58	7	psoriasis	psoriasis	NOUN
dpc-1907	58	8	treatment	treatment	NOUN
dpc-1907	58	9	with	with	ADP
dpc-1907	58	10	biologics	biologic	NOUN
dpc-1907	58	11	and	and	CCONJ
dpc-1907	58	12	small	small	ADJ
dpc-1907	58	13	-	-	PUNCT
dpc-1907	58	14	molecule	molecule	NOUN
dpc-1907	58	15	agents	agent	NOUN
dpc-1907	58	16	is	be	AUX
dpc-1907	58	17	of	of	ADP
dpc-1907	58	18	finite	finite	ADJ
dpc-1907	58	19	duration	duration	NOUN
dpc-1907	58	20	,	,	PUNCT
dpc-1907	58	21	most	most	ADV
dpc-1907	58	22	often	often	ADV
dpc-1907	58	23	due	due	ADJ
dpc-1907	58	24	to	to	ADP
dpc-1907	58	25	efficacy	efficacy	NOUN
dpc-1907	58	26	-	-	PUNCT
dpc-1907	58	27	related	relate	VERB
dpc-1907	58	28	reasons	reason	NOUN
dpc-1907	58	29	.	.	PUNCT
dpc-1907	59	1	•	•	NUM
dpc-1907	59	2	apremilast	apremilast	ADJ
dpc-1907	59	3	survival	survival	NOUN
dpc-1907	59	4	was	be	AUX
dpc-1907	59	5	investigated	investigate	VERB
dpc-1907	59	6	in	in	ADP
dpc-1907	59	7	a	a	DET
dpc-1907	59	8	real	real	ADJ
dpc-1907	59	9	-	-	PUNCT
dpc-1907	59	10	life	life	NOUN
dpc-1907	59	11	setting	setting	NOUN
dpc-1907	59	12	.	.	PUNCT
dpc-1907	60	1	cumulative	cumulative	ADJ
dpc-1907	60	2	survival	survival	NOUN
dpc-1907	60	3	probability	probability	NOUN
dpc-1907	60	4	at	at	ADP
dpc-1907	60	5	24	24	NUM
dpc-1907	60	6	,	,	PUNCT
dpc-1907	60	7	52	52	NUM
dpc-1907	60	8	and	and	CCONJ
dpc-1907	60	9	208	208	NUM
dpc-1907	60	10	weeks	week	NOUN
dpc-1907	60	11	was	be	AUX
dpc-1907	60	12	69.3	69.3	NUM
dpc-1907	60	13	%	%	NOUN
dpc-1907	60	14	,	,	PUNCT
dpc-1907	60	15	52.1	52.1	NUM
dpc-1907	60	16	%	%	NOUN
dpc-1907	60	17	and	and	CCONJ
dpc-1907	60	18	28.1	28.1	NUM
dpc-1907	60	19	%	%	NOUN
dpc-1907	60	20	,	,	PUNCT
dpc-1907	60	21	respectively	respectively	ADV
dpc-1907	60	22	.	.	PUNCT
dpc-1907	61	1	nineteen	nineteen	NUM
dpc-1907	61	2	(	(	PUNCT
dpc-1907	61	3	18.6	18.6	NUM
dpc-1907	61	4	%	%	NOUN
dpc-1907	61	5	)	)	PUNCT
dpc-1907	61	6	,	,	PUNCT
dpc-1907	61	7	24	24	NUM
dpc-1907	61	8	(	(	PUNCT
dpc-1907	61	9	23.5	23.5	NUM
dpc-1907	61	10	%	%	NOUN
dpc-1907	61	11	)	)	PUNCT
dpc-1907	61	12	and	and	CCONJ
dpc-1907	61	13	15	15	NUM
dpc-1907	61	14	(	(	PUNCT
dpc-1907	61	15	14.7	14.7	NUM
dpc-1907	61	16	%	%	NOUN
dpc-1907	61	17	)	)	PUNCT
dpc-1907	61	18	patients	patient	NOUN
dpc-1907	61	19	discontinued	discontinue	VERB
dpc-1907	61	20	apremilast	apremilast	ADJ
dpc-1907	61	21	due	due	ADP
dpc-1907	61	22	to	to	ADP
dpc-1907	61	23	lack	lack	NOUN
dpc-1907	61	24	of	of	ADP
dpc-1907	61	25	efficacy	efficacy	NOUN
dpc-1907	61	26	,	,	PUNCT
dpc-1907	61	27	loss	loss	NOUN
dpc-1907	61	28	of	of	ADP
dpc-1907	61	29	efficacy	efficacy	NOUN
dpc-1907	61	30	and	and	CCONJ
dpc-1907	61	31	adverse	adverse	ADJ
dpc-1907	61	32	reactions	reaction	NOUN
dpc-1907	61	33	,	,	PUNCT
dpc-1907	61	34	respectively	respectively	ADV
dpc-1907	61	35	.	.	PUNCT
dpc-1907	62	1	original	original	ADJ
dpc-1907	62	2	article	article	NOUN
dpc-1907	62	3	|	|	ADV
dpc-1907	62	4	dermatol	dermatol	ADJ
dpc-1907	62	5	pract	pract	NOUN
dpc-1907	62	6	concept	concept	NOUN
dpc-1907	62	7	.	.	PUNCT
dpc-1907	63	1	2022;12(2):e2022076	2022;12(2):e2022076	NUM
dpc-1907	63	2	3	3	NUM
dpc-1907	63	3	patients	patient	NOUN
dpc-1907	63	4	did	do	AUX
dpc-1907	63	5	not	not	PART
dpc-1907	63	6	give	give	VERB
dpc-1907	63	7	consent	consent	NOUN
dpc-1907	63	8	for	for	ADP
dpc-1907	63	9	study	study	NOUN
dpc-1907	63	10	participation	participation	NOUN
dpc-1907	63	11	and	and	CCONJ
dpc-1907	63	12	2	2	NUM
dpc-1907	63	13	patients	patient	NOUN
dpc-1907	63	14	were	be	AUX
dpc-1907	63	15	excluded	exclude	VERB
dpc-1907	63	16	due	due	ADP
dpc-1907	63	17	to	to	ADP
dpc-1907	63	18	incompletely	incompletely	ADV
dpc-1907	63	19	recorded	record	VERB
dpc-1907	63	20	data	datum	NOUN
dpc-1907	63	21	.	.	PUNCT
dpc-1907	64	1	we	we	PRON
dpc-1907	64	2	included	include	VERB
dpc-1907	64	3	102	102	NUM
dpc-1907	64	4	patients	patient	NOUN
dpc-1907	64	5	in	in	ADP
dpc-1907	64	6	our	our	PRON
dpc-1907	64	7	analysis	analysis	NOUN
dpc-1907	64	8	(	(	PUNCT
dpc-1907	64	9	29.4	29.4	NUM
dpc-1907	64	10	%	%	NOUN
dpc-1907	64	11	females	female	NOUN
dpc-1907	64	12	,	,	PUNCT
dpc-1907	64	13	70.6	70.6	NUM
dpc-1907	64	14	%	%	NOUN
dpc-1907	64	15	males	male	NOUN
dpc-1907	64	16	)	)	PUNCT
dpc-1907	64	17	with	with	ADP
dpc-1907	64	18	various	various	ADJ
dpc-1907	64	19	types	type	NOUN
dpc-1907	64	20	of	of	ADP
dpc-1907	64	21	psoriasis	psoriasis	NOUN
dpc-1907	64	22	and	and	CCONJ
dpc-1907	64	23	a	a	DET
dpc-1907	64	24	mean	mean	ADJ
dpc-1907	64	25	age	age	NOUN
dpc-1907	64	26	of	of	ADP
dpc-1907	64	27	55.94	55.94	NUM
dpc-1907	64	28	years	year	NOUN
dpc-1907	64	29	(	(	PUNCT
dpc-1907	64	30	sd	sd	ADP
dpc-1907	64	31	15.21	15.21	NUM
dpc-1907	64	32	)	)	PUNCT
dpc-1907	64	33	.	.	PUNCT
dpc-1907	65	1	patient	patient	PROPN
dpc-1907	65	2	baseline	baseline	PROPN
dpc-1907	65	3	characteristics	characteristic	NOUN
dpc-1907	65	4	are	be	AUX
dpc-1907	65	5	presented	present	VERB
dpc-1907	65	6	in	in	ADP
dpc-1907	65	7	table	table	NOUN
dpc-1907	65	8	1	1	NUM
dpc-1907	65	9	.	.	PUNCT
dpc-1907	66	1	patients	patient	NOUN
dpc-1907	66	2	were	be	AUX
dpc-1907	66	3	followed	follow	VERB
dpc-1907	66	4	-	-	PUNCT
dpc-1907	66	5	up	up	NOUN
dpc-1907	66	6	for	for	ADP
dpc-1907	66	7	a	a	DET
dpc-1907	66	8	total	total	NOUN
dpc-1907	66	9	of	of	ADP
dpc-1907	66	10	26,826	26,826	NUM
dpc-1907	66	11	patient	patient	NOUN
dpc-1907	66	12	-	-	PUNCT
dpc-1907	66	13	weeks	week	NOUN
dpc-1907	66	14	.	.	PUNCT
dpc-1907	67	1	sixty	sixty	NUM
dpc-1907	67	2	-	-	PUNCT
dpc-1907	67	3	five	five	NUM
dpc-1907	67	4	patients	patient	NOUN
dpc-1907	67	5	(	(	PUNCT
dpc-1907	67	6	63.7	63.7	NUM
dpc-1907	67	7	%	%	NOUN
dpc-1907	67	8	)	)	PUNCT
dpc-1907	67	9	had	have	AUX
dpc-1907	67	10	discontinued	discontinue	VERB
dpc-1907	67	11	treatment	treatment	NOUN
dpc-1907	67	12	by	by	ADP
dpc-1907	67	13	lock	lock	NOUN
dpc-1907	67	14	date	date	NOUN
dpc-1907	67	15	:	:	PUNCT
dpc-1907	67	16	19	19	NUM
dpc-1907	67	17	(	(	PUNCT
dpc-1907	67	18	18.6	18.6	NUM
dpc-1907	67	19	%	%	NOUN
dpc-1907	67	20	)	)	PUNCT
dpc-1907	67	21	due	due	ADP
dpc-1907	67	22	to	to	ADP
dpc-1907	67	23	lack	lack	NOUN
dpc-1907	67	24	of	of	ADP
dpc-1907	67	25	efficacy	efficacy	NOUN
dpc-1907	67	26	,	,	PUNCT
dpc-1907	67	27	24	24	NUM
dpc-1907	67	28	(	(	PUNCT
dpc-1907	67	29	23.5	23.5	NUM
dpc-1907	67	30	%	%	NOUN
dpc-1907	67	31	)	)	PUNCT
dpc-1907	67	32	due	due	ADP
dpc-1907	67	33	to	to	ADP
dpc-1907	67	34	loss	loss	NOUN
dpc-1907	67	35	of	of	ADP
dpc-1907	67	36	efficacy	efficacy	NOUN
dpc-1907	67	37	,	,	PUNCT
dpc-1907	67	38	15	15	NUM
dpc-1907	67	39	(	(	PUNCT
dpc-1907	67	40	14.7	14.7	NUM
dpc-1907	67	41	%	%	NOUN
dpc-1907	67	42	)	)	PUNCT
dpc-1907	67	43	due	due	ADP
dpc-1907	67	44	to	to	ADP
dpc-1907	67	45	adverse	adverse	ADJ
dpc-1907	67	46	reactions	reaction	NOUN
dpc-1907	67	47	,	,	PUNCT
dpc-1907	67	48	3	3	NUM
dpc-1907	67	49	(	(	PUNCT
dpc-1907	67	50	2.94	2.94	NUM
dpc-1907	67	51	%	%	NOUN
dpc-1907	67	52	)	)	PUNCT
dpc-1907	67	53	due	due	ADP
dpc-1907	67	54	to	to	ADP
dpc-1907	67	55	other	other	ADJ
dpc-1907	67	56	/	/	SYM
dpc-1907	67	57	personal	personal	ADJ
dpc-1907	67	58	reasons	reason	NOUN
dpc-1907	67	59	,	,	PUNCT
dpc-1907	67	60	while	while	SCONJ
dpc-1907	67	61	4	4	NUM
dpc-1907	67	62	(	(	PUNCT
dpc-1907	67	63	3.92	3.92	NUM
dpc-1907	67	64	%	%	NOUN
dpc-1907	67	65	)	)	PUNCT
dpc-1907	67	66	were	be	AUX
dpc-1907	67	67	lost	lose	VERB
dpc-1907	67	68	to	to	PART
dpc-1907	67	69	follow	follow	VERB
dpc-1907	67	70	-	-	PUNCT
dpc-1907	67	71	up	up	NOUN
dpc-1907	67	72	.	.	PUNCT
dpc-1907	68	1	cumulative	cumulative	ADJ
dpc-1907	68	2	survival	survival	NOUN
dpc-1907	68	3	probability	probability	NOUN
dpc-1907	68	4	at	at	ADP
dpc-1907	68	5	24	24	NUM
dpc-1907	68	6	,	,	PUNCT
dpc-1907	68	7	52	52	NUM
dpc-1907	68	8	,	,	PUNCT
dpc-1907	68	9	104	104	NUM
dpc-1907	68	10	,	,	PUNCT
dpc-1907	68	11	156	156	NUM
dpc-1907	68	12	,	,	PUNCT
dpc-1907	68	13	and	and	CCONJ
dpc-1907	68	14	208	208	NUM
dpc-1907	68	15	weeks	week	NOUN
dpc-1907	68	16	was	be	AUX
dpc-1907	68	17	69.3	69.3	NUM
dpc-1907	68	18	%	%	NOUN
dpc-1907	68	19	,	,	PUNCT
dpc-1907	68	20	52.1	52.1	NUM
dpc-1907	68	21	%	%	NOUN
dpc-1907	68	22	,	,	PUNCT
dpc-1907	68	23	39.8	39.8	NUM
dpc-1907	68	24	%	%	NOUN
dpc-1907	68	25	,	,	PUNCT
dpc-1907	68	26	31.2	31.2	NUM
dpc-1907	68	27	%	%	NOUN
dpc-1907	68	28	,	,	PUNCT
dpc-1907	68	29	and	and	CCONJ
dpc-1907	68	30	28.1	28.1	NUM
dpc-1907	68	31	%	%	NOUN
dpc-1907	68	32	,	,	PUNCT
dpc-1907	68	33	respectively	respectively	ADV
dpc-1907	68	34	(	(	PUNCT
dpc-1907	68	35	figure	figure	NOUN
dpc-1907	68	36	1	1	NUM
dpc-1907	68	37	)	)	PUNCT
dpc-1907	68	38	.	.	PUNCT
dpc-1907	69	1	mean	mean	VERB
dpc-1907	69	2	survival	survival	NOUN
dpc-1907	69	3	time	time	NOUN
dpc-1907	69	4	per	per	ADP
dpc-1907	69	5	reason	reason	NOUN
dpc-1907	69	6	for	for	ADP
dpc-1907	69	7	discontinuation	discontinuation	NOUN
dpc-1907	69	8	and	and	CCONJ
dpc-1907	69	9	pasi75	pasi75	NOUN
dpc-1907	69	10	achievement	achievement	NOUN
dpc-1907	69	11	rates	rate	NOUN
dpc-1907	69	12	are	be	AUX
dpc-1907	69	13	presented	present	VERB
dpc-1907	69	14	in	in	ADP
dpc-1907	69	15	table	table	NOUN
dpc-1907	69	16	1	1	NUM
dpc-1907	69	17	.	.	PUNCT
dpc-1907	70	1	median	median	ADJ
dpc-1907	70	2	survival	survival	NOUN
dpc-1907	70	3	time	time	NOUN
dpc-1907	70	4	for	for	ADP
dpc-1907	70	5	all	all	DET
dpc-1907	70	6	reasons	reason	NOUN
dpc-1907	70	7	for	for	ADP
dpc-1907	70	8	discontinuation	discontinuation	NOUN
dpc-1907	70	9	was	be	AUX
dpc-1907	70	10	58	58	NUM
dpc-1907	70	11	weeks	week	NOUN
dpc-1907	70	12	(	(	PUNCT
dpc-1907	70	13	95	95	NUM
dpc-1907	70	14	%	%	NOUN
dpc-1907	70	15	ci	ci	NOUN
dpc-1907	70	16	40.02	40.02	NUM
dpc-1907	70	17	,	,	PUNCT
dpc-1907	70	18	75.98	75.98	NUM
dpc-1907	70	19	)	)	PUNCT
dpc-1907	70	20	.	.	PUNCT
dpc-1907	71	1	the	the	DET
dpc-1907	71	2	only	only	ADJ
dpc-1907	71	3	covariate	covariate	NOUN
dpc-1907	71	4	found	find	VERB
dpc-1907	71	5	able	able	ADJ
dpc-1907	71	6	to	to	PART
dpc-1907	71	7	predict	predict	VERB
dpc-1907	71	8	drug	drug	NOUN
dpc-1907	71	9	survival	survival	NOUN
dpc-1907	71	10	was	be	AUX
dpc-1907	71	11	the	the	DET
dpc-1907	71	12	combination	combination	NOUN
dpc-1907	71	13	of	of	ADP
dpc-1907	71	14	cardiovascular	cardiovascular	ADJ
dpc-1907	71	15	disease	disease	NOUN
dpc-1907	71	16	and	and	CCONJ
dpc-1907	71	17	diabetes	diabetes	NOUN
dpc-1907	71	18	,	,	PUNCT
dpc-1907	71	19	which	which	PRON
dpc-1907	71	20	was	be	AUX
dpc-1907	71	21	associated	associate	VERB
dpc-1907	71	22	with	with	ADP
dpc-1907	71	23	78	78	NUM
dpc-1907	71	24	%	%	NOUN
dpc-1907	71	25	less	less	ADJ
dpc-1907	71	26	likelihood	likelihood	NOUN
dpc-1907	71	27	of	of	ADP
dpc-1907	71	28	apremilast	apremilast	ADJ
dpc-1907	71	29	discontinuation	discontinuation	NOUN
dpc-1907	71	30	(	(	PUNCT
dpc-1907	71	31	hazard	hazard	NOUN
dpc-1907	71	32	ratio	ratio	NOUN
dpc-1907	71	33	0.22	0.22	NUM
dpc-1907	71	34	,	,	PUNCT
dpc-1907	71	35	p	p	X
dpc-1907	71	36	=	=	NOUN
dpc-1907	71	37	0.035	0.035	NUM
dpc-1907	71	38	)	)	PUNCT
dpc-1907	71	39	.	.	PUNCT
dpc-1907	72	1	table	table	NOUN
dpc-1907	72	2	1	1	NUM
dpc-1907	72	3	.	.	PUNCT
dpc-1907	73	1	patient	patient	ADJ
dpc-1907	73	2	demographic	demographic	ADJ
dpc-1907	73	3	characteristics	characteristic	NOUN
dpc-1907	73	4	and	and	CCONJ
dpc-1907	73	5	apremilast	apremilast	ADJ
dpc-1907	73	6	survival	survival	ADJ
dpc-1907	73	7	female	female	ADJ
dpc-1907	73	8	male	male	NOUN
dpc-1907	73	9	sex†	sex†	NOUN
dpc-1907	73	10	,	,	PUNCT
dpc-1907	73	11	n	n	PROPN
dpc-1907	73	12	(	(	PUNCT
dpc-1907	73	13	%	%	INTJ
dpc-1907	73	14	)	)	PUNCT
dpc-1907	73	15	30	30	NUM
dpc-1907	73	16	(	(	PUNCT
dpc-1907	73	17	29.4	29.4	NUM
dpc-1907	73	18	)	)	SYM
dpc-1907	73	19	72	72	NUM
dpc-1907	73	20	(	(	PUNCT
dpc-1907	73	21	70.6	70.6	NUM
dpc-1907	73	22	)	)	PUNCT
dpc-1907	73	23	age‡	age‡	NOUN
dpc-1907	73	24	,	,	PUNCT
dpc-1907	73	25	years	year	NOUN
dpc-1907	73	26	(	(	PUNCT
dpc-1907	73	27	57.1	57.1	NUM
dpc-1907	73	28	(	(	PUNCT
dpc-1907	73	29	12.89	12.89	NUM
dpc-1907	73	30	,	,	PUNCT
dpc-1907	73	31	57.1	57.1	NUM
dpc-1907	73	32	–	–	PUNCT
dpc-1907	73	33	52.29	52.29	NUM
dpc-1907	73	34	)	)	PUNCT
dpc-1907	73	35	55.17	55.17	NUM
dpc-1907	73	36	(	(	PUNCT
dpc-1907	73	37	16.06	16.06	NUM
dpc-1907	73	38	,	,	PUNCT
dpc-1907	73	39	51.37	51.37	NUM
dpc-1907	73	40	–	–	PUNCT
dpc-1907	73	41	58.97	58.97	NUM
dpc-1907	73	42	)	)	PUNCT
dpc-1907	73	43	bmi§	bmi§	PROPN
dpc-1907	73	44	(	(	PUNCT
dpc-1907	73	45	kg	kg	PROPN
dpc-1907	73	46	/	/	SYM
dpc-1907	73	47	m2	m2	PROPN
dpc-1907	73	48	)	)	PUNCT
dpc-1907	73	49	27.11	27.11	NUM
dpc-1907	73	50	(	(	PUNCT
dpc-1907	73	51	8.01	8.01	NUM
dpc-1907	73	52	)	)	PUNCT
dpc-1907	73	53	27.68	27.68	NUM
dpc-1907	73	54	(	(	PUNCT
dpc-1907	73	55	6.63	6.63	NUM
dpc-1907	73	56	)	)	PUNCT
dpc-1907	73	57	psoriasis	psoriasis	NOUN
dpc-1907	73	58	duration§	duration§	NOUN
dpc-1907	73	59	(	(	PUNCT
dpc-1907	73	60	years	year	NOUN
dpc-1907	73	61	)	)	PUNCT
dpc-1907	73	62	9	9	NUM
dpc-1907	73	63	(	(	PUNCT
dpc-1907	73	64	14	14	NUM
dpc-1907	73	65	)	)	PUNCT
dpc-1907	73	66	13	13	NUM
dpc-1907	73	67	(	(	PUNCT
dpc-1907	73	68	14	14	NUM
dpc-1907	73	69	)	)	PUNCT
dpc-1907	73	70	baseline	baseline	NOUN
dpc-1907	73	71	pasi§	pasi§	X
dpc-1907	73	72	11	11	NUM
dpc-1907	73	73	(	(	PUNCT
dpc-1907	73	74	5.4	5.4	NUM
dpc-1907	73	75	)	)	PUNCT
dpc-1907	73	76	11.7	11.7	NUM
dpc-1907	73	77	(	(	PUNCT
dpc-1907	73	78	7.4	7.4	NUM
dpc-1907	73	79	)	)	PUNCT
dpc-1907	73	80	psoriatic	psoriatic	ADJ
dpc-1907	73	81	arthritis†	arthritis†	NOUN
dpc-1907	73	82	5	5	NUM
dpc-1907	73	83	(	(	PUNCT
dpc-1907	73	84	16.7	16.7	NUM
dpc-1907	73	85	)	)	PUNCT
dpc-1907	73	86	15	15	NUM
dpc-1907	73	87	(	(	PUNCT
dpc-1907	73	88	20.8	20.8	NUM
dpc-1907	73	89	)	)	PUNCT
dpc-1907	73	90	scalp	scalp	NOUN
dpc-1907	73	91	psoriasis†	psoriasis†	VERB
dpc-1907	73	92	28	28	NUM
dpc-1907	73	93	(	(	PUNCT
dpc-1907	73	94	93.3	93.3	NUM
dpc-1907	73	95	)	)	PUNCT
dpc-1907	73	96	55	55	NUM
dpc-1907	73	97	(	(	PUNCT
dpc-1907	73	98	76.4	76.4	NUM
dpc-1907	73	99	)	)	PUNCT
dpc-1907	73	100	nail	nail	NOUN
dpc-1907	73	101	psoriasis†	psoriasis†	VERB
dpc-1907	73	102	13	13	NUM
dpc-1907	73	103	(	(	PUNCT
dpc-1907	73	104	43.3	43.3	NUM
dpc-1907	73	105	)	)	PUNCT
dpc-1907	73	106	35	35	NUM
dpc-1907	73	107	(	(	PUNCT
dpc-1907	73	108	48.6	48.6	NUM
dpc-1907	73	109	)	)	PUNCT
dpc-1907	73	110	smoking†	smoking†	ADJ
dpc-1907	73	111	15	15	NUM
dpc-1907	73	112	(	(	PUNCT
dpc-1907	73	113	50.0	50.0	NUM
dpc-1907	73	114	)	)	PUNCT
dpc-1907	73	115	44	44	NUM
dpc-1907	73	116	(	(	PUNCT
dpc-1907	73	117	61.1	61.1	NUM
dpc-1907	73	118	)	)	PUNCT
dpc-1907	73	119	comorbidities	comorbiditie	NOUN
dpc-1907	73	120	hypertension†	hypertension†	ADV
dpc-1907	73	121	11	11	NUM
dpc-1907	73	122	(	(	PUNCT
dpc-1907	73	123	36.7	36.7	NUM
dpc-1907	73	124	)	)	PUNCT
dpc-1907	73	125	23	23	NUM
dpc-1907	73	126	(	(	PUNCT
dpc-1907	73	127	31.9	31.9	NUM
dpc-1907	73	128	)	)	PUNCT
dpc-1907	73	129	diabetes†	diabetes†	NOUN
dpc-1907	73	130	6	6	NUM
dpc-1907	73	131	(	(	PUNCT
dpc-1907	73	132	20.0	20.0	NUM
dpc-1907	73	133	)	)	PUNCT
dpc-1907	73	134	11	11	NUM
dpc-1907	73	135	(	(	PUNCT
dpc-1907	73	136	15.3	15.3	NUM
dpc-1907	73	137	)	)	PUNCT
dpc-1907	73	138	hyperlipidemia†	hyperlipidemia†	NOUN
dpc-1907	73	139	9	9	NUM
dpc-1907	73	140	(	(	PUNCT
dpc-1907	73	141	30.0	30.0	NUM
dpc-1907	73	142	)	)	PUNCT
dpc-1907	73	143	18	18	NUM
dpc-1907	73	144	(	(	PUNCT
dpc-1907	73	145	25.0	25.0	NUM
dpc-1907	73	146	)	)	PUNCT
dpc-1907	73	147	obesity†	obesity†	ADJ
dpc-1907	73	148	9	9	NUM
dpc-1907	73	149	(	(	PUNCT
dpc-1907	73	150	30.0	30.0	NUM
dpc-1907	73	151	)	)	PUNCT
dpc-1907	73	152	24	24	NUM
dpc-1907	73	153	(	(	PUNCT
dpc-1907	73	154	33.3	33.3	NUM
dpc-1907	73	155	)	)	PUNCT
dpc-1907	73	156	cardiovascular	cardiovascular	ADJ
dpc-1907	73	157	disease†	disease†	ADV
dpc-1907	73	158	5	5	NUM
dpc-1907	73	159	(	(	PUNCT
dpc-1907	73	160	16.7	16.7	NUM
dpc-1907	73	161	)	)	SYM
dpc-1907	73	162	15	15	NUM
dpc-1907	73	163	(	(	PUNCT
dpc-1907	73	164	20.8	20.8	NUM
dpc-1907	73	165	)	)	PUNCT
dpc-1907	73	166	median	median	ADJ
dpc-1907	73	167	survival	survival	NOUN
dpc-1907	73	168	time	time	NOUN
dpc-1907	73	169	(	(	PUNCT
dpc-1907	73	170	all	all	DET
dpc-1907	73	171	reasons	reason	NOUN
dpc-1907	73	172	for	for	ADP
dpc-1907	73	173	discontinuation	discontinuation	NOUN
dpc-1907	73	174	)	)	PUNCT
dpc-1907	73	175	58	58	NUM
dpc-1907	73	176	weeks	week	NOUN
dpc-1907	73	177	95%ci	95%ci	NUM
dpc-1907	73	178	(	(	PUNCT
dpc-1907	73	179	40.02	40.02	NUM
dpc-1907	73	180	,	,	PUNCT
dpc-1907	73	181	75.98	75.98	NUM
dpc-1907	73	182	)	)	PUNCT
dpc-1907	73	183	mean	mean	PROPN
dpc-1907	73	184	survival	survival	NOUN
dpc-1907	73	185	time	time	NOUN
dpc-1907	73	186	in	in	ADP
dpc-1907	73	187	weeks	week	NOUN
dpc-1907	73	188	(	(	PUNCT
dpc-1907	73	189	95	95	NUM
dpc-1907	73	190	%	%	NOUN
dpc-1907	73	191	confidence	confidence	NOUN
dpc-1907	73	192	interval	interval	NOUN
dpc-1907	73	193	)	)	PUNCT
dpc-1907	74	1	all	all	DET
dpc-1907	74	2	reasons	reason	NOUN
dpc-1907	74	3	for	for	ADP
dpc-1907	74	4	discontinuation	discontinuation	NOUN
dpc-1907	74	5	96.75	96.75	NUM
dpc-1907	74	6	(	(	PUNCT
dpc-1907	74	7	78.34	78.34	NUM
dpc-1907	74	8	,	,	PUNCT
dpc-1907	74	9	115.15	115.15	NUM
dpc-1907	74	10	)	)	PUNCT
dpc-1907	74	11	due	due	ADP
dpc-1907	74	12	to	to	ADP
dpc-1907	74	13	lack	lack	NOUN
dpc-1907	74	14	of	of	ADP
dpc-1907	74	15	efficacy	efficacy	NOUN
dpc-1907	74	16	178.06	178.06	NUM
dpc-1907	74	17	(	(	PUNCT
dpc-1907	74	18	159.41	159.41	NUM
dpc-1907	74	19	,	,	PUNCT
dpc-1907	74	20	196.72	196.72	NUM
dpc-1907	74	21	)	)	PUNCT
dpc-1907	74	22	due	due	ADP
dpc-1907	74	23	to	to	ADP
dpc-1907	74	24	loss	loss	NOUN
dpc-1907	74	25	of	of	ADP
dpc-1907	74	26	efficacy	efficacy	NOUN
dpc-1907	74	27	152.35	152.35	NUM
dpc-1907	74	28	(	(	PUNCT
dpc-1907	74	29	130.53	130.53	NUM
dpc-1907	74	30	,	,	PUNCT
dpc-1907	74	31	174.17	174.17	NUM
dpc-1907	74	32	)	)	PUNCT
dpc-1907	74	33	due	due	ADP
dpc-1907	74	34	to	to	ADP
dpc-1907	74	35	adverse	adverse	ADJ
dpc-1907	74	36	events	event	NOUN
dpc-1907	74	37	190.59	190.59	NUM
dpc-1907	74	38	(	(	PUNCT
dpc-1907	74	39	174.45	174.45	NUM
dpc-1907	74	40	,	,	PUNCT
dpc-1907	74	41	206.73	206.73	NUM
dpc-1907	74	42	)	)	PUNCT
dpc-1907	74	43	due	due	ADP
dpc-1907	74	44	to	to	ADP
dpc-1907	74	45	other	other	ADJ
dpc-1907	74	46	reasons	reason	NOUN
dpc-1907	74	47	(	(	PUNCT
dpc-1907	74	48	including	include	VERB
dpc-1907	74	49	loss	loss	NOUN
dpc-1907	74	50	to	to	PART
dpc-1907	74	51	follow	follow	VERB
dpc-1907	74	52	-	-	PUNCT
dpc-1907	74	53	up	up	NOUN
dpc-1907	74	54	)	)	PUNCT
dpc-1907	74	55	211.06	211.06	NUM
dpc-1907	74	56	(	(	PUNCT
dpc-1907	74	57	199.08	199.08	NUM
dpc-1907	74	58	,	,	PUNCT
dpc-1907	74	59	223.05	223.05	NUM
dpc-1907	74	60	)	)	PUNCT
dpc-1907	74	61	week	week	NOUN
dpc-1907	74	62	16	16	NUM
dpc-1907	74	63	week	week	NOUN
dpc-1907	74	64	24	24	NUM
dpc-1907	74	65	week	week	NOUN
dpc-1907	74	66	52	52	NUM
dpc-1907	74	67	week	week	NOUN
dpc-1907	74	68	104	104	NUM
dpc-1907	74	69	week	week	NOUN
dpc-1907	74	70	156	156	NUM
dpc-1907	74	71	pasi75¶	pasi75¶	VERB
dpc-1907	74	72	20.80	20.80	NUM
dpc-1907	74	73	%	%	NOUN
dpc-1907	74	74	46.00	46.00	NUM
dpc-1907	74	75	%	%	NOUN
dpc-1907	74	76	45.74	45.74	NUM
dpc-1907	74	77	%	%	NOUN
dpc-1907	74	78	30.33	30.33	NUM
dpc-1907	74	79	%	%	NOUN
dpc-1907	74	80	13.20	13.20	NUM
dpc-1907	74	81	%	%	NOUN
dpc-1907	74	82	†number	†number	NOUN
dpc-1907	74	83	(	(	PUNCT
dpc-1907	74	84	percentage	percentage	NOUN
dpc-1907	74	85	)	)	PUNCT
dpc-1907	74	86	.	.	PUNCT
dpc-1907	75	1	‡mean	‡mean	NOUN
dpc-1907	75	2	(	(	PUNCT
dpc-1907	75	3	standard	standard	ADJ
dpc-1907	75	4	deviation	deviation	NOUN
dpc-1907	75	5	,	,	PUNCT
dpc-1907	75	6	95	95	NUM
dpc-1907	75	7	%	%	NOUN
dpc-1907	75	8	confidence	confidence	NOUN
dpc-1907	75	9	interval	interval	NOUN
dpc-1907	75	10	)	)	PUNCT
dpc-1907	75	11	.	.	PUNCT
dpc-1907	76	1	§	§	PROPN
dpc-1907	76	2	bmi	bmi	PROPN
dpc-1907	76	3	:	:	PUNCT
dpc-1907	76	4	body	body	NOUN
dpc-1907	76	5	mass	mass	PROPN
dpc-1907	76	6	index	index	PROPN
dpc-1907	76	7	,	,	PUNCT
dpc-1907	76	8	median	median	NOUN
dpc-1907	76	9	(	(	PUNCT
dpc-1907	76	10	interquartile	interquartile	NOUN
dpc-1907	76	11	range	range	NOUN
dpc-1907	76	12	)	)	PUNCT
dpc-1907	76	13	.	.	PUNCT
dpc-1907	77	1	¶pasi75	¶pasi75	ADJ
dpc-1907	77	2	:	:	PUNCT
dpc-1907	77	3	percentage	percentage	NOUN
dpc-1907	77	4	of	of	ADP
dpc-1907	77	5	patients	patient	NOUN
dpc-1907	77	6	having	having	AUX
dpc-1907	77	7	achieved	achieve	VERB
dpc-1907	77	8	75	75	NUM
dpc-1907	77	9	%	%	NOUN
dpc-1907	77	10	reduction	reduction	NOUN
dpc-1907	77	11	in	in	ADP
dpc-1907	77	12	their	their	PRON
dpc-1907	77	13	baseline	baseline	ADJ
dpc-1907	77	14	psoriasis	psoriasis	NOUN
dpc-1907	77	15	area	area	NOUN
dpc-1907	77	16	severity	severity	PROPN
dpc-1907	77	17	index	index	NOUN
dpc-1907	77	18	score	score	NOUN
dpc-1907	77	19	.	.	PUNCT
dpc-1907	78	1	4	4	NUM
dpc-1907	78	2	original	original	ADJ
dpc-1907	78	3	article	article	NOUN
dpc-1907	78	4	|	|	ADV
dpc-1907	78	5	dermatol	dermatol	ADJ
dpc-1907	78	6	pract	pract	NOUN
dpc-1907	78	7	concept	concept	NOUN
dpc-1907	78	8	.	.	PUNCT
dpc-1907	79	1	2022;12(2):e2022076	2022;12(2):e2022076	NUM
dpc-1907	79	2	figure	figure	NOUN
dpc-1907	79	3	1	1	NUM
dpc-1907	79	4	.	.	PUNCT
dpc-1907	79	5	cumulative	cumulative	ADJ
dpc-1907	79	6	survival	survival	NOUN
dpc-1907	79	7	probability	probability	NOUN
dpc-1907	79	8	of	of	ADP
dpc-1907	79	9	apremilast	apremilast	NOUN
dpc-1907	79	10	(	(	PUNCT
dpc-1907	79	11	kaplan	kaplan	PROPN
dpc-1907	79	12	-	-	PUNCT
dpc-1907	79	13	meier	meier	PROPN
dpc-1907	79	14	survival	survival	PROPN
dpc-1907	79	15	curve	curve	PROPN
dpc-1907	79	16	)	)	PUNCT
dpc-1907	79	17	for	for	ADP
dpc-1907	79	18	all	all	DET
dpc-1907	79	19	reasons	reason	NOUN
dpc-1907	79	20	of	of	ADP
dpc-1907	79	21	drug	drug	NOUN
dpc-1907	79	22	discontinuation	discontinuation	NOUN
dpc-1907	79	23	.	.	PUNCT
dpc-1907	80	1	event	event	NOUN
dpc-1907	80	2	:	:	PUNCT
dpc-1907	80	3	drug	drug	NOUN
dpc-1907	80	4	discontinuation	discontinuation	NOUN
dpc-1907	80	5	due	due	ADP
dpc-1907	80	6	to	to	ADP
dpc-1907	80	7	any	any	DET
dpc-1907	80	8	reason	reason	NOUN
dpc-1907	80	9	or	or	CCONJ
dpc-1907	80	10	loss	loss	NOUN
dpc-1907	80	11	to	to	PART
dpc-1907	80	12	follow	follow	VERB
dpc-1907	80	13	-	-	PUNCT
dpc-1907	80	14	up	up	NOUN
dpc-1907	80	15	.	.	PUNCT
dpc-1907	81	1	patients	patient	NOUN
dpc-1907	81	2	still	still	ADV
dpc-1907	81	3	on	on	ADP
dpc-1907	81	4	treatment	treatment	NOUN
dpc-1907	81	5	were	be	AUX
dpc-1907	81	6	censored	censor	VERB
dpc-1907	81	7	at	at	ADP
dpc-1907	81	8	the	the	DET
dpc-1907	81	9	last	last	ADJ
dpc-1907	81	10	available	available	ADJ
dpc-1907	81	11	follow	follow	VERB
dpc-1907	81	12	-	-	PUNCT
dpc-1907	81	13	up	up	ADP
dpc-1907	81	14	visit	visit	NOUN
dpc-1907	81	15	.	.	PUNCT
dpc-1907	82	1	1.0	1.0	NUM
dpc-1907	82	2	apremilast	apremilast	ADJ
dpc-1907	82	3	survival	survival	NOUN
dpc-1907	82	4	all	all	DET
dpc-1907	82	5	reasons	reason	NOUN
dpc-1907	82	6	for	for	ADP
dpc-1907	82	7	discontinuation	discontinuation	NOUN
dpc-1907	82	8	0.8	0.8	NUM
dpc-1907	82	9	0.6	0.6	NUM
dpc-1907	82	10	0.4	0.4	NUM
dpc-1907	82	11	0.2	0.2	NUM
dpc-1907	82	12	0.0	0.0	NUM
dpc-1907	82	13	0	0	NUM
dpc-1907	82	14	weeks	week	NOUN
dpc-1907	82	15	of	of	ADP
dpc-1907	82	16	apremilast	apremilast	ADJ
dpc-1907	82	17	treatment	treatment	NOUN
dpc-1907	82	18	until	until	ADP
dpc-1907	82	19	january	january	PROPN
dpc-1907	82	20	2021	2021	NUM
dpc-1907	82	21	pr	pr	NOUN
dpc-1907	82	22	o	o	NOUN
dpc-1907	82	23	ba	ba	PROPN
dpc-1907	83	1	bi	bi	NOUN
dpc-1907	83	2	li	li	PROPN
dpc-1907	84	1	ty	ty	INTJ
dpc-1907	84	2	o	o	X
dpc-1907	84	3	f	f	X
dpc-1907	84	4	re	re	VERB
dpc-1907	84	5	m	m	PROPN
dpc-1907	84	6	a	a	PRON
dpc-1907	84	7	in	in	ADV
dpc-1907	84	8	in	in	ADP
dpc-1907	84	9	g	g	PROPN
dpc-1907	84	10	o	o	PROPN
dpc-1907	84	11	n	n	PROPN
dpc-1907	84	12	d	d	X
dpc-1907	84	13	ru	ru	NOUN
dpc-1907	84	14	g	g	PROPN
dpc-1907	84	15	50	50	NUM
dpc-1907	84	16	100	100	NUM
dpc-1907	84	17	150	150	NUM
dpc-1907	84	18	200	200	NUM
dpc-1907	84	19	250	250	NUM
dpc-1907	84	20	0.5	0.5	NUM
dpc-1907	84	21	survival	survival	NOUN
dpc-1907	84	22	function	function	NOUN
dpc-1907	84	23	censored	censor	VERB
dpc-1907	84	24	conclusions	conclusion	NOUN
dpc-1907	84	25	according	accord	VERB
dpc-1907	84	26	to	to	ADP
dpc-1907	84	27	our	our	PRON
dpc-1907	84	28	results	result	NOUN
dpc-1907	84	29	,	,	PUNCT
dpc-1907	84	30	approximately	approximately	ADV
dpc-1907	84	31	half	half	NOUN
dpc-1907	84	32	of	of	ADP
dpc-1907	84	33	psoriasis	psoriasis	NOUN
dpc-1907	84	34	patients	patient	NOUN
dpc-1907	84	35	treated	treat	VERB
dpc-1907	84	36	with	with	ADP
dpc-1907	84	37	apremilast	apremilast	NOUN
dpc-1907	84	38	remained	remain	VERB
dpc-1907	84	39	on	on	ADP
dpc-1907	84	40	treatment	treatment	NOUN
dpc-1907	84	41	after	after	ADP
dpc-1907	84	42	one	one	NUM
dpc-1907	84	43	year	year	NOUN
dpc-1907	84	44	and	and	CCONJ
dpc-1907	84	45	a	a	DET
dpc-1907	84	46	little	little	ADJ
dpc-1907	84	47	more	more	ADJ
dpc-1907	84	48	than	than	ADP
dpc-1907	84	49	a	a	DET
dpc-1907	84	50	quarter	quarter	NOUN
dpc-1907	84	51	of	of	ADP
dpc-1907	84	52	them	they	PRON
dpc-1907	84	53	were	be	AUX
dpc-1907	84	54	still	still	ADV
dpc-1907	84	55	receiving	receive	VERB
dpc-1907	84	56	the	the	DET
dpc-1907	84	57	drug	drug	NOUN
dpc-1907	84	58	after	after	ADP
dpc-1907	84	59	4	4	NUM
dpc-1907	84	60	years	year	NOUN
dpc-1907	84	61	of	of	ADP
dpc-1907	84	62	treatment	treatment	NOUN
dpc-1907	84	63	.	.	PUNCT
dpc-1907	85	1	the	the	DET
dpc-1907	85	2	most	most	ADV
dpc-1907	85	3	common	common	ADJ
dpc-1907	85	4	reason	reason	NOUN
dpc-1907	85	5	for	for	ADP
dpc-1907	85	6	discontinuation	discontinuation	NOUN
dpc-1907	85	7	was	be	AUX
dpc-1907	85	8	secondary	secondary	ADJ
dpc-1907	85	9	drug	drug	NOUN
dpc-1907	85	10	failure	failure	NOUN
dpc-1907	85	11	.	.	PUNCT
dpc-1907	86	1	patients	patient	NOUN
dpc-1907	86	2	suffering	suffer	VERB
dpc-1907	86	3	from	from	ADP
dpc-1907	86	4	both	both	DET
dpc-1907	86	5	diabetes	diabetes	NOUN
dpc-1907	86	6	and	and	CCONJ
dpc-1907	86	7	cardiovascular	cardiovascular	ADJ
dpc-1907	86	8	disease	disease	NOUN
dpc-1907	86	9	were	be	AUX
dpc-1907	86	10	significantly	significantly	ADV
dpc-1907	86	11	less	less	ADV
dpc-1907	86	12	likely	likely	ADJ
dpc-1907	86	13	to	to	PART
dpc-1907	86	14	discontinue	discontinue	VERB
dpc-1907	86	15	apremilast	apremilast	VERB
dpc-1907	86	16	.	.	PUNCT
dpc-1907	87	1	limitations	limitation	NOUN
dpc-1907	87	2	of	of	ADP
dpc-1907	87	3	our	our	PRON
dpc-1907	87	4	study	study	NOUN
dpc-1907	87	5	are	be	AUX
dpc-1907	87	6	its	its	PRON
dpc-1907	87	7	retrospective	retrospective	ADJ
dpc-1907	87	8	nature	nature	NOUN
dpc-1907	87	9	,	,	PUNCT
dpc-1907	87	10	lack	lack	NOUN
dpc-1907	87	11	of	of	ADP
dpc-1907	87	12	a	a	DET
dpc-1907	87	13	control	control	NOUN
dpc-1907	87	14	group	group	NOUN
dpc-1907	87	15	and	and	CCONJ
dpc-1907	87	16	absence	absence	NOUN
dpc-1907	87	17	of	of	ADP
dpc-1907	87	18	subgroup	subgroup	NOUN
dpc-1907	87	19	analysis	analysis	NOUN
dpc-1907	87	20	of	of	ADP
dpc-1907	87	21	patients	patient	NOUN
dpc-1907	87	22	having	having	AUX
dpc-1907	87	23	received	receive	VERB
dpc-1907	87	24	concurrent	concurrent	ADJ
dpc-1907	87	25	topical	topical	ADJ
dpc-1907	87	26	treatment	treatment	NOUN
dpc-1907	87	27	.	.	PUNCT
dpc-1907	88	1	according	accord	VERB
dpc-1907	88	2	to	to	ADP
dpc-1907	88	3	real	real	ADJ
dpc-1907	88	4	-	-	PUNCT
dpc-1907	88	5	world	world	NOUN
dpc-1907	88	6	evidence	evidence	NOUN
dpc-1907	88	7	,	,	PUNCT
dpc-1907	88	8	median	median	PROPN
dpc-1907	88	9	apremilast	apremilast	ADJ
dpc-1907	88	10	survival	survival	NOUN
dpc-1907	88	11	ranges	range	VERB
dpc-1907	88	12	from	from	ADP
dpc-1907	88	13	12.5	12.5	NUM
dpc-1907	88	14	to	to	PART
dpc-1907	88	15	65	65	NUM
dpc-1907	88	16	weeks	week	NOUN
dpc-1907	88	17	,	,	PUNCT
dpc-1907	88	18	while	while	SCONJ
dpc-1907	88	19	52	52	NUM
dpc-1907	88	20	-	-	PUNCT
dpc-1907	88	21	week	week	NOUN
dpc-1907	88	22	survival	survival	NOUN
dpc-1907	88	23	probability	probability	NOUN
dpc-1907	88	24	ranges	range	VERB
dpc-1907	88	25	from	from	ADP
dpc-1907	88	26	40.7	40.7	NUM
dpc-1907	88	27	%	%	NOUN
dpc-1907	88	28	to	to	ADP
dpc-1907	88	29	53.4	53.4	NUM
dpc-1907	88	30	%	%	NOUN
dpc-1907	89	1	[	[	X
dpc-1907	89	2	7–11	7–11	NOUN
dpc-1907	89	3	]	]	PUNCT
dpc-1907	89	4	.	.	PUNCT
dpc-1907	90	1	two	two	NUM
dpc-1907	90	2	-	-	PUNCT
dpc-1907	90	3	year	year	NOUN
dpc-1907	90	4	survival	survival	NOUN
dpc-1907	90	5	probability	probability	NOUN
dpc-1907	90	6	was	be	AUX
dpc-1907	90	7	37.4	37.4	NUM
dpc-1907	90	8	%	%	NOUN
dpc-1907	90	9	in	in	ADP
dpc-1907	90	10	a	a	DET
dpc-1907	90	11	japanese	japanese	ADJ
dpc-1907	90	12	study	study	NOUN
dpc-1907	90	13	[	[	X
dpc-1907	90	14	7	7	NUM
dpc-1907	90	15	]	]	PUNCT
dpc-1907	90	16	.	.	PUNCT
dpc-1907	91	1	median	median	ADJ
dpc-1907	91	2	time	time	NOUN
dpc-1907	91	3	to	to	ADP
dpc-1907	91	4	drug	drug	NOUN
dpc-1907	91	5	discontinuation	discontinuation	NOUN
dpc-1907	91	6	was	be	AUX
dpc-1907	91	7	23	23	NUM
dpc-1907	91	8	weeks	week	NOUN
dpc-1907	91	9	for	for	ADP
dpc-1907	91	10	primary	primary	ADJ
dpc-1907	91	11	drug	drug	NOUN
dpc-1907	91	12	failure	failure	NOUN
dpc-1907	91	13	,	,	PUNCT
dpc-1907	91	14	63	63	NUM
dpc-1907	91	15	weeks	week	NOUN
dpc-1907	91	16	for	for	ADP
dpc-1907	91	17	secondary	secondary	ADJ
dpc-1907	91	18	failure	failure	NOUN
dpc-1907	91	19	and	and	CCONJ
dpc-1907	91	20	8	8	NUM
dpc-1907	91	21	weeks	week	NOUN
dpc-1907	91	22	for	for	ADP
dpc-1907	91	23	adverse	adverse	ADJ
dpc-1907	91	24	events	event	NOUN
dpc-1907	91	25	[	[	X
dpc-1907	91	26	12	12	NUM
dpc-1907	91	27	]	]	PUNCT
dpc-1907	91	28	.	.	PUNCT
dpc-1907	92	1	lunder	lunder	PROPN
dpc-1907	92	2	et	et	PROPN
dpc-1907	92	3	al	al	PROPN
dpc-1907	92	4	found	find	VERB
dpc-1907	92	5	that	that	SCONJ
dpc-1907	92	6	apremilast	apremilast	PROPN
dpc-1907	92	7	had	have	VERB
dpc-1907	92	8	the	the	DET
dpc-1907	92	9	lowest	low	ADJ
dpc-1907	92	10	survival	survival	NOUN
dpc-1907	92	11	comparing	compare	VERB
dpc-1907	92	12	to	to	ADP
dpc-1907	92	13	ustekinumab	ustekinumab	NOUN
dpc-1907	92	14	,	,	PUNCT
dpc-1907	92	15	adalimumab	adalimumab	NOUN
dpc-1907	92	16	,	,	PUNCT
dpc-1907	92	17	etanercept	etanercept	NOUN
dpc-1907	92	18	,	,	PUNCT
dpc-1907	92	19	ixekizumab	ixekizumab	NOUN
dpc-1907	92	20	,	,	PUNCT
dpc-1907	92	21	infliximab	infliximab	NOUN
dpc-1907	92	22	and	and	CCONJ
dpc-1907	92	23	secukinumab	secukinumab	NOUN
dpc-1907	92	24	,	,	PUNCT
dpc-1907	92	25	with	with	ADP
dpc-1907	92	26	ustekinumab	ustekinumab	NOUN
dpc-1907	92	27	having	have	VERB
dpc-1907	92	28	the	the	DET
dpc-1907	92	29	longest	long	ADJ
dpc-1907	92	30	duration	duration	NOUN
dpc-1907	92	31	in	in	ADP
dpc-1907	92	32	all	all	DET
dpc-1907	92	33	examined	examine	VERB
dpc-1907	92	34	psoriasis	psoriasis	NOUN
dpc-1907	92	35	patients	patient	NOUN
dpc-1907	92	36	[	[	X
dpc-1907	92	37	3	3	NUM
dpc-1907	92	38	]	]	PUNCT
dpc-1907	92	39	.	.	PUNCT
dpc-1907	93	1	patients	patient	NOUN
dpc-1907	93	2	on	on	ADP
dpc-1907	93	3	apremilast	apremilast	ADJ
dpc-1907	93	4	were	be	AUX
dpc-1907	93	5	more	more	ADV
dpc-1907	93	6	likely	likely	ADJ
dpc-1907	93	7	to	to	PART
dpc-1907	93	8	discontinue	discontinue	VERB
dpc-1907	93	9	treatment	treatment	NOUN
dpc-1907	93	10	compared	compare	VERB
dpc-1907	93	11	to	to	ADP
dpc-1907	93	12	patients	patient	NOUN
dpc-1907	93	13	on	on	ADP
dpc-1907	93	14	methotrexate	methotrexate	NOUN
dpc-1907	93	15	in	in	ADP
dpc-1907	93	16	a	a	DET
dpc-1907	93	17	nationwide	nationwide	ADJ
dpc-1907	93	18	french	french	ADJ
dpc-1907	93	19	study	study	NOUN
dpc-1907	93	20	[	[	X
dpc-1907	93	21	11	11	NUM
dpc-1907	93	22	]	]	PUNCT
dpc-1907	93	23	.	.	PUNCT
dpc-1907	94	1	in	in	ADP
dpc-1907	94	2	a	a	DET
dpc-1907	94	3	cohort	cohort	NOUN
dpc-1907	94	4	of	of	ADP
dpc-1907	94	5	patients	patient	NOUN
dpc-1907	94	6	with	with	ADP
dpc-1907	94	7	palmoplantar	palmoplantar	NOUN
dpc-1907	94	8	pustulosis	pustulosis	NOUN
dpc-1907	94	9	,	,	PUNCT
dpc-1907	94	10	however	however	ADV
dpc-1907	94	11	,	,	PUNCT
dpc-1907	94	12	apremilast	apremilast	PROPN
dpc-1907	94	13	was	be	AUX
dpc-1907	94	14	associated	associate	VERB
dpc-1907	94	15	with	with	ADP
dpc-1907	94	16	the	the	DET
dpc-1907	94	17	longest	long	ADJ
dpc-1907	94	18	survival	survival	NOUN
dpc-1907	94	19	(	(	PUNCT
dpc-1907	94	20	65	65	NUM
dpc-1907	94	21	weeks	week	NOUN
dpc-1907	94	22	)	)	PUNCT
dpc-1907	94	23	comparing	compare	VERB
dpc-1907	94	24	to	to	ADP
dpc-1907	94	25	classic	classic	ADJ
dpc-1907	94	26	systemic	systemic	ADJ
dpc-1907	94	27	treatments	treatment	NOUN
dpc-1907	94	28	,	,	PUNCT
dpc-1907	94	29	such	such	ADJ
dpc-1907	94	30	as	as	ADP
dpc-1907	94	31	cyclosporine	cyclosporine	NOUN
dpc-1907	94	32	,	,	PUNCT
dpc-1907	94	33	acitretin	acitretin	NOUN
dpc-1907	94	34	plus	plus	CCONJ
dpc-1907	94	35	puva	puva	PROPN
dpc-1907	94	36	,	,	PUNCT
dpc-1907	94	37	methotrexate	methotrexate	NOUN
dpc-1907	94	38	,	,	PUNCT
dpc-1907	94	39	acitretin	acitretin	NOUN
dpc-1907	94	40	,	,	PUNCT
dpc-1907	94	41	alitretinoin	alitretinoin	ADJ
dpc-1907	94	42	and	and	CCONJ
dpc-1907	94	43	fumaric	fumaric	ADJ
dpc-1907	94	44	acid	acid	PROPN
dpc-1907	94	45	esters	ester	NOUN
dpc-1907	94	46	[	[	X
dpc-1907	94	47	13	13	NUM
dpc-1907	94	48	]	]	PUNCT
dpc-1907	94	49	.	.	PUNCT
dpc-1907	95	1	primary	primary	ADJ
dpc-1907	95	2	treatment	treatment	NOUN
dpc-1907	95	3	failure	failure	NOUN
dpc-1907	95	4	was	be	AUX
dpc-1907	95	5	the	the	DET
dpc-1907	95	6	most	most	ADV
dpc-1907	95	7	common	common	ADJ
dpc-1907	95	8	reason	reason	NOUN
dpc-1907	95	9	for	for	ADP
dpc-1907	95	10	apremilast	apremilast	ADJ
dpc-1907	95	11	discontinuation	discontinuation	NOUN
dpc-1907	95	12	in	in	ADP
dpc-1907	95	13	a	a	DET
dpc-1907	95	14	usa	usa	PROPN
dpc-1907	95	15	study	study	NOUN
dpc-1907	95	16	comparing	compare	VERB
dpc-1907	95	17	various	various	ADJ
dpc-1907	95	18	biologics	biologic	NOUN
dpc-1907	95	19	and	and	CCONJ
dpc-1907	95	20	apremilast	apremilast	VERB
dpc-1907	95	21	as	as	ADV
dpc-1907	95	22	well	well	ADV
dpc-1907	95	23	as	as	ADP
dpc-1907	95	24	in	in	ADP
dpc-1907	95	25	a	a	DET
dpc-1907	95	26	smaller	small	ADJ
dpc-1907	95	27	austrian	austrian	ADJ
dpc-1907	95	28	study	study	NOUN
dpc-1907	95	29	[	[	X
dpc-1907	95	30	5,10	5,10	NUM
dpc-1907	95	31	]	]	PUNCT
dpc-1907	95	32	.	.	PUNCT
dpc-1907	96	1	loss	loss	NOUN
dpc-1907	96	2	of	of	ADP
dpc-1907	96	3	efficacy	efficacy	NOUN
dpc-1907	96	4	was	be	AUX
dpc-1907	96	5	the	the	DET
dpc-1907	96	6	main	main	ADJ
dpc-1907	96	7	reason	reason	NOUN
dpc-1907	96	8	for	for	ADP
dpc-1907	96	9	apremilast	apremilast	ADJ
dpc-1907	96	10	cessation	cessation	NOUN
dpc-1907	96	11	in	in	ADP
dpc-1907	96	12	a	a	DET
dpc-1907	96	13	japanese	japanese	ADJ
dpc-1907	96	14	study	study	NOUN
dpc-1907	96	15	(	(	PUNCT
dpc-1907	96	16	46.4	46.4	NUM
dpc-1907	96	17	%	%	NOUN
dpc-1907	96	18	)	)	PUNCT
dpc-1907	97	1	[	[	X
dpc-1907	97	2	9	9	NUM
dpc-1907	97	3	]	]	PUNCT
dpc-1907	97	4	.	.	PUNCT
dpc-1907	98	1	apremilast	apremilast	PROPN
dpc-1907	98	2	survival	survival	NOUN
dpc-1907	98	3	was	be	AUX
dpc-1907	98	4	significantly	significantly	ADV
dpc-1907	98	5	reduced	reduce	VERB
dpc-1907	98	6	in	in	ADP
dpc-1907	98	7	patients	patient	NOUN
dpc-1907	98	8	with	with	ADP
dpc-1907	98	9	scalp	scalp	NOUN
dpc-1907	98	10	psoriasis	psoriasis	NOUN
dpc-1907	98	11	(	(	PUNCT
dpc-1907	98	12	p	p	NOUN
dpc-1907	98	13	=	=	NOUN
dpc-1907	98	14	0.001	0.001	NUM
dpc-1907	98	15	)	)	PUNCT
dpc-1907	98	16	in	in	ADP
dpc-1907	98	17	a	a	DET
dpc-1907	98	18	small	small	ADJ
dpc-1907	98	19	spanish	spanish	ADJ
dpc-1907	98	20	study	study	NOUN
dpc-1907	98	21	[	[	X
dpc-1907	98	22	12	12	NUM
dpc-1907	98	23	]	]	PUNCT
dpc-1907	98	24	.	.	PUNCT
dpc-1907	99	1	the	the	DET
dpc-1907	99	2	results	result	NOUN
dpc-1907	99	3	of	of	ADP
dpc-1907	99	4	this	this	DET
dpc-1907	99	5	study	study	NOUN
dpc-1907	99	6	are	be	AUX
dpc-1907	99	7	comparable	comparable	ADJ
dpc-1907	99	8	to	to	ADP
dpc-1907	99	9	other	other	ADJ
dpc-1907	99	10	real	real	ADJ
dpc-1907	99	11	-	-	PUNCT
dpc-1907	99	12	life	life	NOUN
dpc-1907	99	13	apremilast	apremilast	ADJ
dpc-1907	99	14	survival	survival	PROPN
dpc-1907	99	15	data	data	PROPN
dpc-1907	99	16	.	.	PUNCT
dpc-1907	100	1	median	median	PROPN
dpc-1907	100	2	apremilast	apremilast	PROPN
dpc-1907	100	3	survival	survival	NOUN
dpc-1907	100	4	at	at	ADP
dpc-1907	100	5	52	52	NUM
dpc-1907	100	6	weeks	week	NOUN
dpc-1907	100	7	was	be	AUX
dpc-1907	100	8	found	find	VERB
dpc-1907	100	9	less	less	ADJ
dpc-1907	100	10	than	than	ADP
dpc-1907	100	11	that	that	PRON
dpc-1907	100	12	of	of	ADP
dpc-1907	100	13	other	other	ADJ
dpc-1907	100	14	systemic	systemic	ADJ
dpc-1907	100	15	treatments	treatment	NOUN
dpc-1907	100	16	for	for	ADP
dpc-1907	100	17	psoriasis	psoriasis	NOUN
dpc-1907	100	18	,	,	PUNCT
dpc-1907	100	19	as	as	SCONJ
dpc-1907	100	20	presented	present	VERB
dpc-1907	100	21	in	in	ADP
dpc-1907	100	22	various	various	ADJ
dpc-1907	100	23	real	real	ADJ
dpc-1907	100	24	-	-	PUNCT
dpc-1907	100	25	life	life	NOUN
dpc-1907	100	26	reports	report	NOUN
dpc-1907	100	27	.	.	PUNCT
dpc-1907	101	1	references	reference	NOUN
dpc-1907	101	2	1	1	NUM
dpc-1907	101	3	.	.	PUNCT
dpc-1907	101	4	papp	papp	PROPN
dpc-1907	101	5	k	k	PROPN
dpc-1907	101	6	,	,	PUNCT
dpc-1907	101	7	reich	reich	PROPN
dpc-1907	101	8	k	k	PROPN
dpc-1907	101	9	,	,	PUNCT
dpc-1907	101	10	leonardi	leonardi	PROPN
dpc-1907	101	11	cl	cl	PROPN
dpc-1907	101	12	,	,	PUNCT
dpc-1907	101	13	et	et	PROPN
dpc-1907	101	14	al	al	PROPN
dpc-1907	101	15	.	.	PROPN
dpc-1907	102	1	apremilast	apremilast	PROPN
dpc-1907	102	2	,	,	PUNCT
dpc-1907	102	3	an	an	DET
dpc-1907	102	4	oral	oral	ADJ
dpc-1907	102	5	phosphodiesterase	phosphodiesterase	NOUN
dpc-1907	102	6	4	4	NUM
dpc-1907	102	7	(	(	PUNCT
dpc-1907	102	8	pde4	pde4	NOUN
dpc-1907	102	9	)	)	PUNCT
dpc-1907	102	10	inhibitor	inhibitor	NOUN
dpc-1907	102	11	,	,	PUNCT
dpc-1907	102	12	in	in	ADP
dpc-1907	102	13	patients	patient	NOUN
dpc-1907	102	14	with	with	ADP
dpc-1907	102	15	moderate	moderate	ADJ
dpc-1907	102	16	to	to	ADP
dpc-1907	102	17	severe	severe	ADJ
dpc-1907	102	18	plaque	plaque	NOUN
dpc-1907	102	19	psoriasis	psoriasis	NOUN
dpc-1907	102	20	:	:	PUNCT
dpc-1907	102	21	results	result	NOUN
dpc-1907	102	22	of	of	ADP
dpc-1907	102	23	a	a	DET
dpc-1907	102	24	phase	phase	NOUN
dpc-1907	102	25	iii	iii	NOUN
dpc-1907	102	26	,	,	PUNCT
dpc-1907	102	27	randomized	randomize	VERB
dpc-1907	102	28	,	,	PUNCT
dpc-1907	102	29	controlled	control	VERB
dpc-1907	102	30	trial	trial	NOUN
dpc-1907	102	31	(	(	PUNCT
dpc-1907	102	32	efficacy	efficacy	NOUN
dpc-1907	102	33	and	and	CCONJ
dpc-1907	102	34	safety	safety	NOUN
dpc-1907	102	35	trial	trial	NOUN
dpc-1907	102	36	evaluating	evaluate	VERB
dpc-1907	102	37	the	the	DET
dpc-1907	102	38	effects	effect	NOUN
dpc-1907	102	39	of	of	ADP
dpc-1907	102	40	apremilast	apremilast	NOUN
dpc-1907	102	41	in	in	ADP
dpc-1907	102	42	psoriasis	psoriasis	NOUN
dpc-1907	103	1	[	[	X
dpc-1907	103	2	esteem	esteem	NOUN
dpc-1907	103	3	]	]	X
dpc-1907	103	4	1	1	NUM
dpc-1907	103	5	)	)	PUNCT
dpc-1907	103	6	.	.	PUNCT
dpc-1907	104	1	j	j	PROPN
dpc-1907	104	2	am	be	AUX
dpc-1907	104	3	acad	acad	ADJ
dpc-1907	104	4	dermatol	dermatol	NOUN
dpc-1907	104	5	.	.	PUNCT
dpc-1907	105	1	2015;73(1):37–49	2015;73(1):37–49	NUM
dpc-1907	105	2	.	.	PUNCT
dpc-1907	105	3	doi	doi	NOUN
dpc-1907	105	4	:	:	PUNCT
dpc-1907	105	5	10.1016	10.1016	NUM
dpc-1907	105	6	/	/	SYM
dpc-1907	105	7	j.jaad.2015.03.049	j.jaad.2015.03.049	PROPN
dpc-1907	105	8	.	.	PUNCT
dpc-1907	106	1	pmid	pmid	NOUN
dpc-1907	106	2	:	:	PUNCT
dpc-1907	106	3	26089047	26089047	NUM
dpc-1907	106	4	.	.	PUNCT
dpc-1907	107	1	original	original	ADJ
dpc-1907	107	2	article	article	NOUN
dpc-1907	107	3	|	|	ADV
dpc-1907	107	4	dermatol	dermatol	ADJ
dpc-1907	107	5	pract	pract	NOUN
dpc-1907	107	6	concept	concept	NOUN
dpc-1907	107	7	.	.	PUNCT
dpc-1907	108	1	2022;12(2):e2022076	2022;12(2):e2022076	NUM
dpc-1907	108	2	5	5	NUM
dpc-1907	108	3	2	2	NUM
dpc-1907	108	4	.	.	PUNCT
dpc-1907	109	1	paul	paul	PROPN
dpc-1907	109	2	c	c	PROPN
dpc-1907	109	3	,	,	PUNCT
dpc-1907	109	4	cather	cather	PROPN
dpc-1907	109	5	j	j	PROPN
dpc-1907	109	6	,	,	PUNCT
dpc-1907	109	7	gooderham	gooderham	PROPN
dpc-1907	109	8	m	m	PROPN
dpc-1907	109	9	,	,	PUNCT
dpc-1907	109	10	et	et	PROPN
dpc-1907	109	11	al	al	PROPN
dpc-1907	109	12	.	.	PROPN
dpc-1907	109	13	efficacy	efficacy	NOUN
dpc-1907	109	14	and	and	CCONJ
dpc-1907	109	15	safety	safety	NOUN
dpc-1907	109	16	of	of	ADP
dpc-1907	109	17	apremilast	apremilast	ADJ
dpc-1907	109	18	,	,	PUNCT
dpc-1907	109	19	an	an	DET
dpc-1907	109	20	oral	oral	ADJ
dpc-1907	109	21	phosphodiesterase	phosphodiesterase	NOUN
dpc-1907	109	22	4	4	NUM
dpc-1907	109	23	inhibitor	inhibitor	NOUN
dpc-1907	109	24	,	,	PUNCT
dpc-1907	109	25	in	in	ADP
dpc-1907	109	26	patients	patient	NOUN
dpc-1907	109	27	with	with	ADP
dpc-1907	109	28	moderate	moderate	ADJ
dpc-1907	109	29	-	-	PUNCT
dpc-1907	109	30	to	to	ADP
dpc-1907	109	31	-	-	PUNCT
dpc-1907	109	32	severe	severe	ADJ
dpc-1907	109	33	plaque	plaque	NOUN
dpc-1907	109	34	psoriasis	psoriasis	NOUN
dpc-1907	109	35	over	over	ADP
dpc-1907	109	36	52	52	NUM
dpc-1907	109	37	weeks	week	NOUN
dpc-1907	109	38	:	:	PUNCT
dpc-1907	109	39	a	a	DET
dpc-1907	109	40	phase	phase	NOUN
dpc-1907	109	41	iii	iii	NOUN
dpc-1907	109	42	,	,	PUNCT
dpc-1907	109	43	randomized	randomize	VERB
dpc-1907	109	44	controlled	control	VERB
dpc-1907	109	45	trial	trial	NOUN
dpc-1907	109	46	(	(	PUNCT
dpc-1907	109	47	esteem	esteem	NOUN
dpc-1907	109	48	2	2	NUM
dpc-1907	109	49	)	)	PUNCT
dpc-1907	109	50	.	.	PUNCT
dpc-1907	110	1	br	br	PROPN
dpc-1907	110	2	j	j	PROPN
dpc-1907	110	3	dermatol	dermatol	NOUN
dpc-1907	110	4	.	.	PUNCT
dpc-1907	111	1	2015;173(6):1387	2015;173(6):1387	NUM
dpc-1907	111	2	–	–	PUNCT
dpc-1907	111	3	1399	1399	NUM
dpc-1907	111	4	.	.	PUNCT
dpc-1907	112	1	doi	doi	NOUN
dpc-1907	112	2	:	:	PUNCT
dpc-1907	112	3	10.1111	10.1111	NUM
dpc-1907	112	4	/	/	SYM
dpc-1907	112	5	bjd.14164	bjd.14164	NOUN
dpc-1907	112	6	.	.	PUNCT
dpc-1907	113	1	pmid	pmid	NOUN
dpc-1907	113	2	:	:	PUNCT
dpc-1907	113	3	26357944	26357944	NUM
dpc-1907	113	4	.	.	PUNCT
dpc-1907	114	1	3	3	X
dpc-1907	114	2	.	.	X
dpc-1907	114	3	lunder	lunder	PROPN
dpc-1907	114	4	t	t	PROPN
dpc-1907	114	5	,	,	PUNCT
dpc-1907	114	6	zorko	zorko	PROPN
dpc-1907	114	7	ms	ms	PROPN
dpc-1907	114	8	,	,	PUNCT
dpc-1907	114	9	kolar	kolar	PROPN
dpc-1907	114	10	nk	nk	PROPN
dpc-1907	114	11	,	,	PUNCT
dpc-1907	114	12	et	et	PROPN
dpc-1907	114	13	al	al	PROPN
dpc-1907	114	14	.	.	PROPN
dpc-1907	114	15	drug	drug	PROPN
dpc-1907	114	16	survival	survival	NOUN
dpc-1907	114	17	of	of	ADP
dpc-1907	114	18	biological	biological	ADJ
dpc-1907	114	19	therapy	therapy	NOUN
dpc-1907	114	20	is	be	AUX
dpc-1907	114	21	showing	show	VERB
dpc-1907	114	22	class	class	NOUN
dpc-1907	114	23	effect	effect	NOUN
dpc-1907	114	24	:	:	PUNCT
dpc-1907	114	25	updated	update	VERB
dpc-1907	114	26	results	result	NOUN
dpc-1907	114	27	from	from	ADP
dpc-1907	114	28	slovenian	slovenian	ADJ
dpc-1907	114	29	national	national	ADJ
dpc-1907	114	30	registry	registry	NOUN
dpc-1907	114	31	of	of	ADP
dpc-1907	114	32	psoriasis	psoriasis	NOUN
dpc-1907	114	33	.	.	PUNCT
dpc-1907	115	1	int	int	NOUN
dpc-1907	115	2	j	j	PROPN
dpc-1907	115	3	dermatol	dermatol	NOUN
dpc-1907	115	4	.	.	PUNCT
dpc-1907	116	1	2019;58(6):631	2019;58(6):631	NUM
dpc-1907	116	2	–	–	PUNCT
dpc-1907	116	3	641	641	NUM
dpc-1907	116	4	.	.	PUNCT
dpc-1907	117	1	doi	doi	NOUN
dpc-1907	117	2	:	:	PUNCT
dpc-1907	117	3	10.1111	10.1111	NUM
dpc-1907	117	4	/	/	SYM
dpc-1907	117	5	ijd.14429	ijd.14429	NOUN
dpc-1907	117	6	.	.	PUNCT
dpc-1907	117	7	pmid	pmid	NOUN
dpc-1907	117	8	:	:	PUNCT
dpc-1907	117	9	30973647	30973647	NUM
dpc-1907	117	10	.	.	PUNCT
dpc-1907	118	1	4	4	X
dpc-1907	118	2	.	.	X
dpc-1907	118	3	yiu	yiu	PROPN
dpc-1907	118	4	zzn	zzn	NOUN
dpc-1907	118	5	,	,	PUNCT
dpc-1907	118	6	mason	mason	PROPN
dpc-1907	118	7	kj	kj	PROPN
dpc-1907	118	8	,	,	PUNCT
dpc-1907	118	9	hampton	hampton	PROPN
dpc-1907	118	10	pj	pj	PROPN
dpc-1907	118	11	,	,	PUNCT
dpc-1907	118	12	et	et	PROPN
dpc-1907	118	13	al	al	PROPN
dpc-1907	118	14	.	.	PROPN
dpc-1907	118	15	drug	drug	PROPN
dpc-1907	118	16	survival	survival	NOUN
dpc-1907	118	17	of	of	ADP
dpc-1907	118	18	adalimumab	adalimumab	PROPN
dpc-1907	118	19	,	,	PUNCT
dpc-1907	118	20	ustekinumab	ustekinumab	NOUN
dpc-1907	118	21	and	and	CCONJ
dpc-1907	118	22	secukinumab	secukinumab	NOUN
dpc-1907	118	23	in	in	ADP
dpc-1907	118	24	patients	patient	NOUN
dpc-1907	118	25	with	with	ADP
dpc-1907	118	26	psoriasis	psoriasis	NOUN
dpc-1907	118	27	:	:	PUNCT
dpc-1907	118	28	a	a	DET
dpc-1907	118	29	prospective	prospective	ADJ
dpc-1907	118	30	cohort	cohort	NOUN
dpc-1907	118	31	study	study	NOUN
dpc-1907	118	32	from	from	ADP
dpc-1907	118	33	the	the	DET
dpc-1907	118	34	british	british	PROPN
dpc-1907	118	35	association	association	PROPN
dpc-1907	118	36	of	of	ADP
dpc-1907	118	37	dermatologists	dermatologists	PROPN
dpc-1907	118	38	biologics	biologic	NOUN
dpc-1907	118	39	and	and	CCONJ
dpc-1907	118	40	immunomodulators	immunomodulator	NOUN
dpc-1907	118	41	register	register	VERB
dpc-1907	118	42	(	(	PUNCT
dpc-1907	118	43	badbir	badbir	NOUN
dpc-1907	118	44	)	)	PUNCT
dpc-1907	118	45	.	.	PUNCT
dpc-1907	119	1	br	br	PROPN
dpc-1907	119	2	j	j	PROPN
dpc-1907	119	3	dermatol	dermatol	NOUN
dpc-1907	119	4	.	.	PUNCT
dpc-1907	120	1	2020;183(2):294–302	2020;183(2):294–302	PROPN
dpc-1907	120	2	.	.	PUNCT
dpc-1907	120	3	doi	doi	PROPN
dpc-1907	120	4	:	:	PUNCT
dpc-1907	120	5	10.1111/	10.1111/	NUM
dpc-1907	120	6	bjd.18981	bjd.18981	NOUN
dpc-1907	120	7	.	.	PUNCT
dpc-1907	121	1	pmid	pmid	NOUN
dpc-1907	121	2	:	:	PUNCT
dpc-1907	121	3	32124442	32124442	NUM
dpc-1907	121	4	.	.	PUNCT
dpc-1907	122	1	5	5	NUM
dpc-1907	122	2	.	.	X
dpc-1907	122	3	zeb	zeb	PROPN
dpc-1907	122	4	l	l	PROPN
dpc-1907	122	5	,	,	PUNCT
dpc-1907	122	6	mhaskar	mhaskar	PROPN
dpc-1907	122	7	r	r	PROPN
dpc-1907	122	8	,	,	PUNCT
dpc-1907	122	9	lewis	lewis	PROPN
dpc-1907	122	10	s	s	PROPN
dpc-1907	122	11	,	,	PUNCT
dpc-1907	122	12	et	et	PROPN
dpc-1907	122	13	al	al	PROPN
dpc-1907	122	14	.	.	PUNCT
dpc-1907	123	1	real	real	ADJ
dpc-1907	123	2	-	-	PUNCT
dpc-1907	123	3	world	world	NOUN
dpc-1907	123	4	drug	drug	NOUN
dpc-1907	123	5	survival	survival	NOUN
dpc-1907	123	6	and	and	CCONJ
dpc-1907	123	7	reasons	reason	NOUN
dpc-1907	123	8	for	for	ADP
dpc-1907	123	9	treatment	treatment	NOUN
dpc-1907	123	10	discontinuation	discontinuation	NOUN
dpc-1907	123	11	of	of	ADP
dpc-1907	123	12	biologics	biologic	NOUN
dpc-1907	123	13	and	and	CCONJ
dpc-1907	123	14	apremilast	apremilast	VERB
dpc-1907	123	15	in	in	ADP
dpc-1907	123	16	patients	patient	NOUN
dpc-1907	123	17	with	with	ADP
dpc-1907	123	18	psoriasis	psoriasis	NOUN
dpc-1907	123	19	in	in	ADP
dpc-1907	123	20	an	an	DET
dpc-1907	123	21	academic	academic	ADJ
dpc-1907	123	22	center	center	NOUN
dpc-1907	123	23	.	.	PUNCT
dpc-1907	124	1	dermatol	dermatol	NOUN
dpc-1907	124	2	ther	ther	ADV
dpc-1907	124	3	.	.	PUNCT
dpc-1907	125	1	2021;34(2):e14826	2021;34(2):e14826	NUM
dpc-1907	125	2	.	.	PUNCT
dpc-1907	126	1	doi	doi	NOUN
dpc-1907	126	2	:	:	PUNCT
dpc-1907	126	3	10.1111	10.1111	NUM
dpc-1907	126	4	/	/	SYM
dpc-1907	126	5	dth.14826	dth.14826	PROPN
dpc-1907	126	6	.	.	PUNCT
dpc-1907	127	1	epmid	epmid	ADP
dpc-1907	127	2	:	:	PUNCT
dpc-1907	127	3	33527682	33527682	NUM
dpc-1907	127	4	.	.	PUNCT
dpc-1907	128	1	6	6	X
dpc-1907	128	2	.	.	X
dpc-1907	128	3	crowley	crowley	PROPN
dpc-1907	128	4	j	j	PROPN
dpc-1907	128	5	,	,	PUNCT
dpc-1907	128	6	thaçi	thaçi	PROPN
dpc-1907	128	7	d	d	PROPN
dpc-1907	128	8	,	,	PUNCT
dpc-1907	128	9	joly	joly	PROPN
dpc-1907	128	10	p	p	PROPN
dpc-1907	128	11	,	,	PUNCT
dpc-1907	128	12	et	et	PROPN
dpc-1907	128	13	al	al	PROPN
dpc-1907	128	14	.	.	PUNCT
dpc-1907	129	1	long	long	ADJ
dpc-1907	129	2	-	-	PUNCT
dpc-1907	129	3	term	term	NOUN
dpc-1907	129	4	safety	safety	NOUN
dpc-1907	129	5	and	and	CCONJ
dpc-1907	129	6	tolerability	tolerability	NOUN
dpc-1907	129	7	of	of	ADP
dpc-1907	129	8	apremilast	apremilast	NOUN
dpc-1907	129	9	in	in	ADP
dpc-1907	129	10	patients	patient	NOUN
dpc-1907	129	11	with	with	ADP
dpc-1907	129	12	psoriasis	psoriasis	NOUN
dpc-1907	129	13	:	:	PUNCT
dpc-1907	129	14	pooled	pool	VERB
dpc-1907	129	15	safety	safety	NOUN
dpc-1907	129	16	analysis	analysis	NOUN
dpc-1907	129	17	for	for	SCONJ
dpc-1907	129	18	≥156	≥156	NOUN
dpc-1907	129	19	weeks	week	NOUN
dpc-1907	129	20	from	from	ADP
dpc-1907	129	21	2	2	NUM
dpc-1907	129	22	phase	phase	NOUN
dpc-1907	129	23	3	3	NUM
dpc-1907	129	24	,	,	PUNCT
dpc-1907	129	25	randomized	randomize	VERB
dpc-1907	129	26	,	,	PUNCT
dpc-1907	129	27	controlled	control	VERB
dpc-1907	129	28	trials	trial	NOUN
dpc-1907	129	29	(	(	PUNCT
dpc-1907	129	30	esteem	esteem	NOUN
dpc-1907	129	31	1	1	NUM
dpc-1907	129	32	and	and	CCONJ
dpc-1907	129	33	2	2	NUM
dpc-1907	129	34	)	)	PUNCT
dpc-1907	129	35	.	.	PUNCT
dpc-1907	130	1	j	j	PROPN
dpc-1907	130	2	am	be	AUX
dpc-1907	130	3	acad	acad	ADJ
dpc-1907	130	4	dermatol	dermatol	NOUN
dpc-1907	130	5	.	.	PUNCT
dpc-1907	131	1	2017;77(2):310	2017;77(2):310	NUM
dpc-1907	131	2	-	-	PUNCT
dpc-1907	131	3	317	317	NUM
dpc-1907	131	4	.	.	PUNCT
dpc-1907	132	1	e1	e1	NOUN
dpc-1907	132	2	.	.	PUNCT
dpc-1907	133	1	doi	doi	NOUN
dpc-1907	133	2	:	:	PUNCT
dpc-1907	133	3	10.1016	10.1016	NUM
dpc-1907	133	4	/	/	SYM
dpc-1907	133	5	j.jaad.2017.01.052	j.jaad.2017.01.052	PROPN
dpc-1907	133	6	.	.	PUNCT
dpc-1907	134	1	pmid	pmid	NOUN
dpc-1907	134	2	:	:	PUNCT
dpc-1907	134	3	28416342	28416342	NUM
dpc-1907	134	4	.	.	PUNCT
dpc-1907	135	1	7	7	X
dpc-1907	135	2	.	.	X
dpc-1907	135	3	saruwatari	saruwatari	PROPN
dpc-1907	135	4	h.	h.	PROPN
dpc-1907	135	5	real	real	ADJ
dpc-1907	135	6	-	-	PUNCT
dpc-1907	135	7	world	world	NOUN
dpc-1907	135	8	experiences	experience	NOUN
dpc-1907	135	9	of	of	ADP
dpc-1907	135	10	apremilast	apremilast	NOUN
dpc-1907	135	11	in	in	ADP
dpc-1907	135	12	clinics	clinic	NOUN
dpc-1907	135	13	for	for	ADP
dpc-1907	135	14	japanese	japanese	ADJ
dpc-1907	135	15	patients	patient	NOUN
dpc-1907	135	16	with	with	ADP
dpc-1907	135	17	psoriasis	psoriasis	NOUN
dpc-1907	135	18	.	.	PUNCT
dpc-1907	136	1	j	j	PROPN
dpc-1907	136	2	dermatol	dermatol	NOUN
dpc-1907	136	3	.	.	PUNCT
dpc-1907	137	1	2019;46(12):1166	2019;46(12):1166	NUM
dpc-1907	137	2	–	–	PUNCT
dpc-1907	137	3	1169	1169	NUM
dpc-1907	137	4	.	.	PUNCT
dpc-1907	138	1	doi	doi	NOUN
dpc-1907	138	2	:	:	PUNCT
dpc-1907	138	3	10.1111/1346	10.1111/1346	NUM
dpc-1907	138	4	-	-	PUNCT
dpc-1907	138	5	8138.15104	8138.15104	NOUN
dpc-1907	138	6	.	.	PUNCT
dpc-1907	139	1	pmid	pmid	NOUN
dpc-1907	139	2	:	:	PUNCT
dpc-1907	139	3	31587350	31587350	NUM
dpc-1907	139	4	.	.	PUNCT
dpc-1907	140	1	8	8	X
dpc-1907	140	2	.	.	X
dpc-1907	140	3	lee	lee	PROPN
dpc-1907	140	4	eb	eb	PROPN
dpc-1907	140	5	,	,	PUNCT
dpc-1907	140	6	amin	amin	PROPN
dpc-1907	140	7	m	m	PROPN
dpc-1907	140	8	,	,	PUNCT
dpc-1907	140	9	wu	wu	PROPN
dpc-1907	140	10	jj	jj	PROPN
dpc-1907	140	11	.	.	PROPN
dpc-1907	140	12	drug	drug	PROPN
dpc-1907	140	13	survival	survival	NOUN
dpc-1907	140	14	of	of	ADP
dpc-1907	140	15	apremilast	apremilast	NOUN
dpc-1907	140	16	in	in	ADP
dpc-1907	140	17	patients	patient	NOUN
dpc-1907	140	18	treated	treat	VERB
dpc-1907	140	19	for	for	ADP
dpc-1907	140	20	psoriasis	psoriasis	NOUN
dpc-1907	140	21	in	in	ADP
dpc-1907	140	22	a	a	DET
dpc-1907	140	23	real	real	ADJ
dpc-1907	140	24	-	-	PUNCT
dpc-1907	140	25	world	world	NOUN
dpc-1907	140	26	setting	setting	NOUN
dpc-1907	140	27	.	.	PUNCT
dpc-1907	141	1	j	j	PROPN
dpc-1907	141	2	am	be	AUX
dpc-1907	141	3	acad	acad	ADJ
dpc-1907	141	4	dermatol	dermatol	NOUN
dpc-1907	141	5	.	.	PUNCT
dpc-1907	142	1	2018;79(4):760–761	2018;79(4):760–761	NUM
dpc-1907	142	2	.	.	X
dpc-1907	142	3	doi	doi	NOUN
dpc-1907	142	4	:	:	PUNCT
dpc-1907	142	5	10.1016	10.1016	NUM
dpc-1907	142	6	/	/	SYM
dpc-1907	142	7	j.jaad.2018.03.028	j.jaad.2018.03.028	NOUN
dpc-1907	142	8	.	.	PUNCT
dpc-1907	143	1	pmid	pmid	NOUN
dpc-1907	143	2	:	:	PUNCT
dpc-1907	143	3	29588246	29588246	NUM
dpc-1907	143	4	.	.	PUNCT
dpc-1907	144	1	9	9	X
dpc-1907	144	2	.	.	X
dpc-1907	144	3	kishimoto	kishimoto	PROPN
dpc-1907	144	4	m	m	PROPN
dpc-1907	144	5	,	,	PUNCT
dpc-1907	144	6	komine	komine	PROPN
dpc-1907	144	7	m	m	PROPN
dpc-1907	144	8	,	,	PUNCT
dpc-1907	144	9	kamiya	kamiya	PROPN
dpc-1907	144	10	k	k	PROPN
dpc-1907	144	11	,	,	PUNCT
dpc-1907	144	12	sugai	sugai	PROPN
dpc-1907	144	13	j	j	PROPN
dpc-1907	144	14	,	,	PUNCT
dpc-1907	144	15	ohtsuki	ohtsuki	ADJ
dpc-1907	144	16	m.	m.	NOUN
dpc-1907	144	17	drug	drug	NOUN
dpc-1907	144	18	survival	survival	NOUN
dpc-1907	144	19	of	of	ADP
dpc-1907	144	20	apremilast	apremilast	NOUN
dpc-1907	144	21	in	in	ADP
dpc-1907	144	22	a	a	DET
dpc-1907	144	23	real	real	ADJ
dpc-1907	144	24	-	-	PUNCT
dpc-1907	144	25	world	world	NOUN
dpc-1907	144	26	setting	setting	NOUN
dpc-1907	144	27	.	.	PUNCT
dpc-1907	145	1	j	j	PROPN
dpc-1907	145	2	dermatol	dermatol	NOUN
dpc-1907	145	3	.	.	PUNCT
dpc-1907	146	1	2019;46(7):615	2019;46(7):615	PROPN
dpc-1907	146	2	-	-	PUNCT
dpc-1907	146	3	617	617	NUM
dpc-1907	146	4	.	.	PUNCT
dpc-1907	147	1	doi	doi	NOUN
dpc-1907	147	2	:	:	PUNCT
dpc-1907	147	3	10.1111/1346	10.1111/1346	NUM
dpc-1907	147	4	-	-	SYM
dpc-1907	147	5	8138.14943	8138.14943	NUM
dpc-1907	147	6	.	.	PUNCT
dpc-1907	148	1	pmid	pmid	NOUN
dpc-1907	148	2	:	:	PUNCT
dpc-1907	148	3	31180150	31180150	NUM
dpc-1907	148	4	.	.	PUNCT
dpc-1907	149	1	10	10	NUM
dpc-1907	149	2	.	.	X
dpc-1907	149	3	vujic	vujic	PROPN
dpc-1907	150	1	i	i	PROPN
dpc-1907	150	2	,	,	PUNCT
dpc-1907	150	3	herman	herman	PROPN
dpc-1907	150	4	r	r	PROPN
dpc-1907	150	5	,	,	PUNCT
dpc-1907	150	6	sanlorenzo	sanlorenzo	NOUN
dpc-1907	150	7	m	m	NOUN
dpc-1907	150	8	,	,	PUNCT
dpc-1907	150	9	et	et	PROPN
dpc-1907	150	10	al	al	PROPN
dpc-1907	150	11	.	.	PROPN
dpc-1907	150	12	apremilast	apremilast	VERB
dpc-1907	150	13	in	in	ADP
dpc-1907	150	14	psoriasis	psoriasis	NOUN
dpc-1907	150	15	–	–	PUNCT
dpc-1907	150	16	a	a	DET
dpc-1907	150	17	prospective	prospective	ADJ
dpc-1907	150	18	real	real	ADJ
dpc-1907	150	19	-	-	PUNCT
dpc-1907	150	20	world	world	NOUN
dpc-1907	150	21	study	study	NOUN
dpc-1907	150	22	.	.	PUNCT
dpc-1907	151	1	j	j	PROPN
dpc-1907	151	2	eur	eur	PROPN
dpc-1907	151	3	acad	acad	PROPN
dpc-1907	151	4	dermatology	dermatology	NOUN
dpc-1907	151	5	venereol	venereol	PROPN
dpc-1907	151	6	2018;32(2):254–259	2018;32(2):254–259	NUM
dpc-1907	151	7	.	.	PUNCT
dpc-1907	152	1	doi	doi	NOUN
dpc-1907	152	2	:	:	PUNCT
dpc-1907	152	3	10.1111	10.1111	NUM
dpc-1907	152	4	/	/	SYM
dpc-1907	152	5	jdv.14598	jdv.14598	NOUN
dpc-1907	152	6	.	.	PUNCT
dpc-1907	153	1	pmid	pmid	NOUN
dpc-1907	153	2	:	:	PUNCT
dpc-1907	153	3	28925560	28925560	NUM
dpc-1907	153	4	.	.	PUNCT
dpc-1907	154	1	11	11	NUM
dpc-1907	154	2	.	.	PUNCT
dpc-1907	155	1	sbidian	sbidian	PROPN
dpc-1907	155	2	e	e	PROPN
dpc-1907	155	3	,	,	PUNCT
dpc-1907	155	4	billionnet	billionnet	PROPN
dpc-1907	155	5	c	c	PROPN
dpc-1907	155	6	,	,	PUNCT
dpc-1907	155	7	weill	weill	PROPN
dpc-1907	155	8	a	a	X
dpc-1907	155	9	,	,	PUNCT
dpc-1907	155	10	maura	maura	PROPN
dpc-1907	155	11	g	g	PROPN
dpc-1907	155	12	,	,	PUNCT
dpc-1907	155	13	mezzarobba	mezzarobba	NOUN
dpc-1907	155	14	m.	m.	NOUN
dpc-1907	155	15	persistence	persistence	NOUN
dpc-1907	155	16	of	of	ADP
dpc-1907	155	17	apremilast	apremilast	NOUN
dpc-1907	155	18	in	in	ADP
dpc-1907	155	19	moderate	moderate	ADJ
dpc-1907	155	20	-	-	PUNCT
dpc-1907	155	21	to	to	ADP
dpc-1907	155	22	-	-	PUNCT
dpc-1907	155	23	severe	severe	ADJ
dpc-1907	155	24	psoriasis	psoriasis	NOUN
dpc-1907	155	25	:	:	PUNCT
dpc-1907	155	26	a	a	DET
dpc-1907	155	27	real	real	ADJ
dpc-1907	155	28	-	-	PUNCT
dpc-1907	155	29	world	world	NOUN
dpc-1907	155	30	analysis	analysis	NOUN
dpc-1907	155	31	of	of	ADP
dpc-1907	155	32	14	14	NUM
dpc-1907	155	33	147	147	NUM
dpc-1907	155	34	apremilastand	apremilastand	ADJ
dpc-1907	155	35	methotrexate	methotrexate	NOUN
dpc-1907	155	36	-	-	PUNCT
dpc-1907	155	37	naive	naive	ADJ
dpc-1907	155	38	patients	patient	NOUN
dpc-1907	155	39	in	in	ADP
dpc-1907	155	40	the	the	DET
dpc-1907	155	41	french	french	ADJ
dpc-1907	155	42	national	national	PROPN
dpc-1907	155	43	health	health	PROPN
dpc-1907	155	44	insurance	insurance	NOUN
dpc-1907	155	45	database	database	NOUN
dpc-1907	155	46	.	.	PUNCT
dpc-1907	156	1	br	br	PROPN
dpc-1907	156	2	j	j	PROPN
dpc-1907	156	3	dermatol	dermatol	NOUN
dpc-1907	156	4	.	.	PUNCT
dpc-1907	157	1	2020;182(3):690	2020;182(3):690	NUM
dpc-1907	157	2	-	-	SYM
dpc-1907	157	3	697	697	NUM
dpc-1907	157	4	.	.	PUNCT
dpc-1907	157	5	doi	doi	NOUN
dpc-1907	157	6	:	:	PUNCT
dpc-1907	157	7	10.1111	10.1111	NUM
dpc-1907	157	8	/	/	SYM
dpc-1907	157	9	bjd.18047	bjd.18047	NUM
dpc-1907	157	10	.	.	PUNCT
dpc-1907	158	1	pmid	pmid	NOUN
dpc-1907	158	2	:	:	PUNCT
dpc-1907	158	3	31021438	31021438	NUM
dpc-1907	158	4	.	.	PUNCT
dpc-1907	159	1	12	12	NUM
dpc-1907	159	2	.	.	PUNCT
dpc-1907	160	1	sahuquillo	sahuquillo	PROPN
dpc-1907	160	2	-	-	PUNCT
dpc-1907	160	3	torralba	torralba	PROPN
dpc-1907	160	4	a	a	PRON
dpc-1907	160	5	,	,	PUNCT
dpc-1907	160	6	de	de	X
dpc-1907	160	7	unamuno	unamuno	PROPN
dpc-1907	160	8	bustos	bustos	PROPN
dpc-1907	160	9	b	b	PROPN
dpc-1907	160	10	,	,	PUNCT
dpc-1907	160	11	rodríguez	rodríguez	PROPN
dpc-1907	160	12	serna	serna	PROPN
dpc-1907	160	13	m	m	PROPN
dpc-1907	160	14	,	,	PUNCT
dpc-1907	160	15	monte	monte	PROPN
dpc-1907	160	16	boquet	boquet	NOUN
dpc-1907	160	17	e	e	NOUN
dpc-1907	160	18	,	,	PUNCT
dpc-1907	160	19	botella	botella	PROPN
dpc-1907	160	20	estrada	estrada	PROPN
dpc-1907	160	21	r.	r.	PROPN
dpc-1907	160	22	treatment	treatment	PROPN
dpc-1907	160	23	persistence	persistence	NOUN
dpc-1907	160	24	and	and	CCONJ
dpc-1907	160	25	safety	safety	NOUN
dpc-1907	160	26	of	of	ADP
dpc-1907	160	27	apremilast	apremilast	NOUN
dpc-1907	160	28	in	in	ADP
dpc-1907	160	29	psoriasis	psoriasis	NOUN
dpc-1907	160	30	:	:	PUNCT
dpc-1907	160	31	experience	experience	NOUN
dpc-1907	160	32	with	with	ADP
dpc-1907	160	33	30	30	NUM
dpc-1907	160	34	patients	patient	NOUN
dpc-1907	160	35	in	in	ADP
dpc-1907	160	36	routine	routine	ADJ
dpc-1907	160	37	clinical	clinical	ADJ
dpc-1907	160	38	practice	practice	NOUN
dpc-1907	160	39	.	.	PUNCT
dpc-1907	161	1	actas	actas	PROPN
dpc-1907	161	2	dermosifiliogr	dermosifiliogr	NOUN
dpc-1907	161	3	(	(	PUNCT
dpc-1907	161	4	engl	engl	PROPN
dpc-1907	161	5	ed	ed	NOUN
dpc-1907	161	6	)	)	PUNCT
dpc-1907	161	7	.	.	PUNCT
dpc-1907	162	1	2020;111(5):415418	2020;111(5):415418	NUM
dpc-1907	162	2	.	.	PUNCT
dpc-1907	163	1	doi	doi	NOUN
dpc-1907	163	2	:	:	PUNCT
dpc-1907	163	3	10.1016	10.1016	NUM
dpc-1907	163	4	/	/	SYM
dpc-1907	163	5	j.ad.2018.10.031	j.ad.2018.10.031	PROPN
dpc-1907	163	6	.	.	PUNCT
dpc-1907	164	1	pmid	pmid	PROPN
dpc-1907	164	2	:	:	PUNCT
dpc-1907	164	3	32423533.s	32423533.s	PROPN
dpc-1907	164	4	13	13	NUM
dpc-1907	164	5	.	.	PUNCT
dpc-1907	165	1	kromer	kromer	PROPN
dpc-1907	165	2	c	c	PROPN
dpc-1907	165	3	,	,	PUNCT
dpc-1907	165	4	wilsmann	wilsmann	PROPN
dpc-1907	165	5	-	-	PUNCT
dpc-1907	165	6	theis	theis	PROPN
dpc-1907	165	7	d	d	PROPN
dpc-1907	165	8	,	,	PUNCT
dpc-1907	165	9	gerdes	gerdes	PROPN
dpc-1907	165	10	s	s	PROPN
dpc-1907	165	11	,	,	PUNCT
dpc-1907	165	12	et	et	PROPN
dpc-1907	165	13	al	al	PROPN
dpc-1907	165	14	.	.	PROPN
dpc-1907	165	15	drug	drug	PROPN
dpc-1907	165	16	survival	survival	NOUN
dpc-1907	165	17	and	and	CCONJ
dpc-1907	165	18	reasons	reason	NOUN
dpc-1907	165	19	for	for	ADP
dpc-1907	165	20	drug	drug	NOUN
dpc-1907	165	21	discontinuation	discontinuation	NOUN
dpc-1907	165	22	in	in	ADP
dpc-1907	165	23	palmoplantar	palmoplantar	ADJ
dpc-1907	165	24	pustulosis	pustulosis	NOUN
dpc-1907	165	25	:	:	PUNCT
dpc-1907	165	26	a	a	DET
dpc-1907	165	27	retrospective	retrospective	ADJ
dpc-1907	165	28	multicenter	multicenter	NOUN
dpc-1907	165	29	study	study	NOUN
dpc-1907	165	30	.	.	PUNCT
dpc-1907	166	1	j	j	PROPN
dpc-1907	166	2	dtsch	dtsch	PROPN
dpc-1907	166	3	dermatol	dermatol	NOUN
dpc-1907	166	4	ges	ge	NOUN
dpc-1907	166	5	.	.	PROPN
dpc-1907	167	1	2019;17(5):503–516	2019;17(5):503–516	PROPN
dpc-1907	167	2	.	.	PUNCT
dpc-1907	167	3	doi	doi	NOUN
dpc-1907	167	4	:	:	PUNCT
dpc-1907	167	5	10.1111	10.1111	NUM
dpc-1907	167	6	/	/	SYM
dpc-1907	167	7	ddg.13834	ddg.13834	PROPN
dpc-1907	167	8	.	.	PUNCT
dpc-1907	168	1	pmid	pmid	NOUN
dpc-1907	168	2	:	:	PUNCT
dpc-1907	168	3	30994260	30994260	NUM
dpc-1907	168	4	.	.	PUNCT
dpc-1907	169	1	pmcid	pmcid	ADJ
dpc-1907	169	2	:	:	PUNCT
dpc-1907	169	3	pmc6850581	pmc6850581	NOUN
dpc-1907	169	4	.	.	PUNCT